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Tuberculosis (TB) is an infectious and fatal disease that ranks as the second leading killer 
worldwide. It is caused by Mycobacterium tuberculosis (Mtb) which is an obligate intracellular 
parasite that colonizes the alveolar macrophages of the immune system. The major health 
concern associated with TB is its co-infection with HIV and the development of strains with 
multi-drug resistance. The elimination of TB has been hindered due to the lack of understanding 
of the survival strategies used by this pathogen. 
 
Thus, research towards discovering new effective antibacterial drugs is necessary and a group 
of Mtb kinase enzymes were targeted in this study because these enzymes are crucial for 
metabolism, pathogenesis and, hence, the survival of Mtb. Kinases are a group of structurally 
distinct and diverse proteins that catalyze the transfer of the phosphate group from high energy 
donor molecules such as ATP (or GTP) to a substrate. The phosphorylation of proteins modifies 
the activity of specific proteins which is subsequently used to control complex cellular processes 
within Mtb. 
 
The starting point of this research targeted eight specific Mtb kinases namely; Nucleoside 
diphosphokinase, Homoserine kinase, Acetate kinase, Glycerol kinase, Thiamine 
monophosphate kinase, Ribokinase, Aspartokinase and Shikimate kinase. The aim of this 
project was to subclone the gene sequences for these eight recombinant Mtb kinases and 
express them in Escherichia coli, to purify the proteins and determine their activity. In the effort 
to find new lead compounds, the final stage of this study focused on the basic screening of the 
TB kinases against an extract prepared from Pelargonium sidoides, a medicinal plant, to identify 
any inhibitory effects. Although this traditional medicinal plant has been broadly researched and 
extensively used to treat TB, there is still a lack of understanding of this plant’s scientific curative 
effect.  
 
Various molecular and biochemical methods were used to achieve the aims of this project. The 
putative gene sequence was obtained from the annotated genome of H37Rv, deposited at NCBI 
as NC_000962.2. The genes encoding the kinases were successfully PCR-amplified from 
genomic DNA, cloned into an expression vector in-frame with a C- or N-terminal 6-histidine-tag 
and expressed in E. coli BL21 (DE3). The purification of the protein was complex, but various 
different methods and techniques were explored to obtain sufficient amounts of protein. The 
functional characterization of the kinases involved an HPLC enzyme assay that showed that the 
recombinant kinases were active. These enzymes were then screened against the potential 
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inhibitory compounds in P. sidoides using enzyme assays to generate dose-response curves.  
This allowed an effective comparison not only of the Mtb kinases’ activity under normal 
conditions but also the kinases’ activity in the presence of a potential inhibitor. Overall, the 
inhibition of the enzymes required the presence of higher concentrations of the P. sidoides 
extract. However, the SK enzyme results presented a significantly higher inhibition and the 
lowest IC50 value, in comparison to the other kinases, which makes this kinase an attractive 
potential drug target against TB.  
 
In summation, cloning and purification of SK was successful, resulting in a concentration of 
2030 µg/ml of purified enzyme and its activity analysis demonstrated enzyme functionality. This 
activity was reduced to zero in the presence of 1 x 102 mg/ml dilution of P. sidoides plant 
extract.  
 
This research conducted has extended the quality of information available in this field of study. 
These interesting results, proposing and identifying SK as a suitable potential target can be a 
starting point to significantly contribute and progress in this field of research, with the eventual 
goal of developing a drug to combat this fatal disease.  
 
Key Terms:  
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vii 
 
Acknowledgments 
 
This dissertation would not have been possible without the guidance and inspiration of my 
mentor, Dr Robyn Roth. Through her unwavering supervision, she has been pivotal to me 
successfully developing my skills and techniques in this field of study. I could not have imagined 
having a better advisor and mentor.  
 
I would like to sincerely thank Professor Colin Kenyon, who presented me with the opportunity 
to pursue this phenomenal research project. His leadership and immense knowledge has 
contributed immeasurably to my growth and development as a research scientist. 
 
A special thanks to Professor John Dewar for his continuous support, enthusiasm, motivation 
and invaluable advice which he had provided throughout this process. I wish to express my 
appreciation to him, for assisting me, to advance my academic career. I would also like to thank 
him for his kind words, patience and wisdom. 
 
I would like to thank all my colleagues and the staff at CSIR-Biosciences for their assistance 
and for providing me access to the facilities required to complete my work.  
 
I would like to acknowledge and thank the National Research Foundation for awarding me with 
the Innovation Masters Scholarship.  
 
I owe my deepest gratitude to my Dad, Shane Lukman; Mum, Prishiela Lukman; and sister, 
Karishma Lukman for their affection, blessings and faith in me. I would like to thank Keshan 
Pillay for his unequivocal support, encouragement and love throughout this journey. Lastly, I 
would like to thank God, my Bhagwan, my Hanuman, for giving me the ability and strength to 
achieve this goal.  
 
 
 
viii 
 
Index  
 
Declaration ................................................................................................................................. iii 
Summary ................................................................................................................................... iv 
Acknowledgments ..................................................................................................................... vii 
Index ....................................................................................................................................... viii 
List of figures ............................................................................................................................ xii 
List of tables .............................................................................................................................. xv 
List of abbreviations ................................................................................................................. xvi 
Chapter 1: Introduction ............................................................................................................... 1 
1.1 Tuberculosis (TB): A fatal disease ............................................................................... 2 
1.2 The infectious agent: Mycobacterium tuberculosis (Mtb) .............................................. 3 
1.3 Kinases: potential Mtb drug targets .............................................................................. 5 
1.3.1 Nucleoside diphosphokinase (NDK) ........................................................................... 5 
1.3.2 Homoserine kinase (HSK) .......................................................................................... 6 
1.3.3 Acetate kinase (AK) ................................................................................................... 8 
1.3.4 Glycerol kinase (GK) .................................................................................................. 9 
1.3.5 Thiamine monophosphate kinase (ThiL) ...................................................................10 
1.3.6 Ribokinase (RBKS) ...................................................................................................11 
1.3.7 Aspartokinase (AsK) .................................................................................................12 
1.3.8 Shikimate kinase (SK) ...............................................................................................14 
1.4 Pelargonium sidoides: a medicinal plant .....................................................................16 
1.5 Research Formulation .................................................................................................17 
Chapter 2: Gene Identification, Amplification and Cloning .........................................................19 
2.1 Introduction .................................................................................................................19 
2.1.1 Overview of objectives ..............................................................................................19 
ix 
 
2.1.2 Mtb genes .................................................................................................................20 
2.2 Materials and Methods ................................................................................................21 
2.2.1 Gene identification ....................................................................................................21 
2.2.2 DNA amplification ......................................................................................................24 
2.2.3 Cloning into pGEM®-T Easy vector (Promega. USA) ................................................25 
2.2.4 Identification of successful cloned products ...............................................................27 
2.2.5 Cloning into selected pET vector ...............................................................................29 
2.2.6 Nucleotide sequencing ..............................................................................................32 
2.3 Results and Discussion ...............................................................................................33 
2.3.1 Template authentication ............................................................................................33 
2.3.2 DNA amplification ......................................................................................................33 
2.3.3 Plasmid construction .................................................................................................36 
2.3.4 E. coli Transformations..............................................................................................39 
2.3.5 Restriction enzyme digests gels ................................................................................39 
2.3.6 Nucleotide sequencing ..............................................................................................42 
2.4 Chapter conclusion .....................................................................................................42 
Chapter 3: E. coli expression and Protein Purification ...............................................................43 
3.1 Introduction .................................................................................................................43 
3.2 Materials and Methods ................................................................................................45 
3.2.1 E. coli expression and cultivation by induction ...........................................................45 
3.2.2 Lysis of cells by sonication ........................................................................................45 
3.2.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) analysis 46 
3.2.4 Protein Purification ....................................................................................................46 
3.2.5 Dialysis .....................................................................................................................49 
3.2.6 Protein Quantitation ..................................................................................................50 
3.3 Results and Discussion ...............................................................................................51 
3.3.1 E. coli expression ......................................................................................................51 
x 
 
3.3.2 Protein production evaluation ....................................................................................51 
3.3.3 SDS-PAGE analysis of purified protein .....................................................................52 
3.3.4 Determination of Protein Quantitation ........................................................................55 
3.4 Chapter conclusion .....................................................................................................56 
Chapter 4: Functional characterization of enzymes ...................................................................57 
4.1 Introduction .................................................................................................................57 
4.2 Materials and Methods ................................................................................................59 
4.2.1 Enzyme activity analysis by High Performance Liquid Chromatography (HPLC) .......59 
4.2.2 ATP concentration gradient assays ...........................................................................60 
4.3 Results and Discussion ...............................................................................................62 
4.3.1 Determination of enzyme activity ...............................................................................62 
4.3.2 ATP concentration gradient assay outcome ..............................................................63 
4.4 Chapter conclusion .....................................................................................................69 
Chapter 5: Screening of the effect of extracts of Pelargonium sidoides on Mtb kinase activity ..70 
5.1 Introduction .................................................................................................................70 
5.2 Materials and Methods ................................................................................................72 
5.2.1 Plant Harvesting and Extraction ................................................................................72 
5.2.2 Plant inhibitory screens .............................................................................................72 
5.3 Results and Discussion ...............................................................................................75 
5.3.1 Plant material ............................................................................................................75 
5.3.2 Pelargonium sidoides concentration gradient assay outcome ...................................75 
5.3.3 Plant inhibitory screens evaluation ............................................................................80 
5.4 Chapter conclusion .....................................................................................................86 
Chapter 6: Concluding discussion and future recommendations ...............................................87 
6.1 Concluding discussion ................................................................................................87 
6.1.1 Insights into combating TB ........................................................................................87 
6.1.2 Using kinases as potential drug targets .....................................................................87 
xi 
 
6.1.3 The gap between traditional P. sidoides usage and modern pharmaceuticals ...........89 
6.2 Future recommendations ............................................................................................91 
Appendices ...............................................................................................................................92 
References ............................................................................................................................. 107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
List of figures 
 
Chapter 1 
Figure 1-1: Estimated Worlds TB incidence rates, 2012 (World Health Organisation. 2013) ...... 2 
Figure 1-2: Transmission and growth of Mycobacterium tuberculosis (Davis. 2007) .................. 3 
Figure 1-3: Structure of Mycobacterium tuberculosis (Microbiology In Pictures. 2013) ............... 4 
Figure 1-4: 3D Structure of NDK from Dictyostelium discoideum ............................................... 6 
Figure 1-5: 3D Structure of HSK from Methanocaldococcus jannaschii ...................................... 7 
Figure 1-6: 3D Structure of AK Methanosarcina thermophile...................................................... 9 
Figure 1-7: 3D Structure of GK from Escherichia coli ................................................................10 
Figure 1-8: 3D Structure of ThiL from Aquifex aeolicus .............................................................11 
Figure 1-9: 3D Structure of RBKS from Escherichia coli ............................................................12 
Figure 1-10: 3D Structure of AsK from Corynebacterium glutamicum .......................................14 
Figure 1-11: 3D Structure of SK from Mycobacterium tuberculosid ...........................................15 
Figure 1-12: Image of Pelargonium sidoides plant (Research On Medical. 2013) .....................16 
Chapter 2 
Figure 2-1: Agarose gel electrophoresis of the H37Rv genomic DNA template .........................33 
Figure 2-2: Agarose gel electrophoresis of the kinase amplicons obtained by PCR amplification 
using H37Rv genomic DNA as the template .............................................................................34 
Figure 2-3: Agarose gel electrophoresis of the kinase amplicons obtained by PCR amplification 
using H37Rv genomic DNA as the template .............................................................................35 
Figure 2-4: Complete plasmid maps ..........................................................................................37 
Figure 2-5: Complete plasmids maps ........................................................................................38 
Figure 2-6: Agarose gel electrophoresis of the recombinant vector-kinase inserts eluted from 
agarose gels following restriction enzyme digestions ................................................................40 
Figure 2-7: Agarose gel electrophoresis of the recombinant vector-kinase inserts following 
restriction enzyme digestions ....................................................................................................41 
Chapter 3 
Figure 3-1: SDS-PAGE gels of the Mtb his-tagged kinases purified from E. coli BL21 (DE3) ....53 
Figure 3-2: SDS-PAGE gels of the Mtb his-tagged kinases purified from E. coli BL21 (DE3) ....54 
Chapter 4 
Figure 4-1: ADP production by His-NDK as a measure of TDP phosphorylating activity ...........64 
xiii 
 
Figure 4-2: ADP production by His-HSK as a measure of homoserine phosphorylating activity 
 .................................................................................................................................................64 
Figure 4-3: ADP production by His-AK as a measure of Na-acetate phosphorylating activity ....65 
Figure 4-4: ADP production by His-GK as a measure of glycerol phosphorylating activity .........65 
Figure 4-5: ADP production by His-ThiL as a measure of TMP phosphorylating activity ............66 
Figure 4-6: ADP production by His-RBKS as a measure of D-ribose phosphorylating activity ...66 
Figure 4-7: ADP production by His-AsK as a measure of aspartate phosphorylating activity .....67 
Figure 4-8: ADP production by His-SK as a measure of shikimic acid phosphorylating activity .67 
Chapter 5 
Figure 5-1: ADP production by His-NDK as a measure against a LOG concentration gradient of 
P. sidoides extract .....................................................................................................................76 
Figure 5-2: ADP production by His-HSK as a measure against a LOG concentration gradient of 
P. sidoides extract. ....................................................................................................................76 
Figure 5-3: AK - ADP production by His-AK as a measure against a LOG concentration gradient 
of P. sidoides extract .................................................................................................................77 
Figure 5-4: GK - ADP production by His-GK as a measure against a LOG concentration gradient 
of P. sidoides extract .................................................................................................................77 
Figure 5-5: ADP production by His-ThiL as a measure against a LOG concentration gradient of 
P. sidoides extract .....................................................................................................................78 
Figure 5-6: ADP production by His-RBKS as a measure against a LOG concentration gradient 
of P. sidoides extract .................................................................................................................78 
Figure 5-7: ADP production by His-AsK as a measure against a LOG concentration gradient of 
P. sidoides extract .....................................................................................................................79 
Figure 5-8: ADP production by His-SK as a measure against a LOG concentration gradient of P. 
sidoides extract .........................................................................................................................79 
Figure 5-9: Bar graph of ADP production by His-NDK as measured against a concentration 
gradient of P. sidoides plant extract ..........................................................................................81 
Figure 5-10: Bar graph of ADP production by His-HSK as measured against a concentration 
gradient of P. sidoides plant extract ..........................................................................................81 
Figure 5-11: Bar graph of ADP production by His-AK as measured against a concentration 
gradient of P. sidoides plant extract ..........................................................................................82 
Figure 5-12: Bar graph of ADP production by His-GK as measured against a concentration 
gradient of P. sidoides plant extract ..........................................................................................82 
xiv 
 
Figure 5-13: Bar graph of ADP production by His-ThiL as measured against a concentration 
gradient of P. sidoides plant extract ..........................................................................................83 
Figure 5-14: Bar graph of ADP production by His-RBKS as measured against a concentration 
gradient of P. sidoides plant extract ..........................................................................................83 
Figure 5-15: Bar graph of ADP production by His-AsK as measured against a concentration 
gradient of P. sidoides plant extract ..........................................................................................84 
Figure 5-16: Bar graph of ADP production by His-SK as measured against a concentration 
gradient of P. sidoides plant extract ..........................................................................................84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
List of tables 
 
Chapter 2 
Table 2-1: Particular forward and reverse primers used to amplify specific kinase genes. Note 
also preferred Novagen vector for each construct. ....................................................................22 
Table 2-2: Kinase genes and their relevant information .............................................................23 
Table 2-3: Kinase genes and their specific annealing temperatures for the PCR reactions .......24 
Table 2-4: Kinase genes and their respective restriction enzymes and buffers used to confirm 
insert size ..................................................................................................................................28 
Table 2-5: Kinase genes with their vectors and respective restriction enzymes and buffers used 
for digests .................................................................................................................................30 
Table 2-6: A list of kinase genes and their respective restriction enzymes and buffer used to 
confirm final digestion ...............................................................................................................32 
Chapter 3 
Table 3-1: Recommended purification method according to kinase solubility ............................47 
Table 3-2: Dialysis buffers used to solubilise NDK, HSK, AK, GK, ThiL, RBKS, AsK and SK 
kinase proteins ..........................................................................................................................50 
Table 3-3: Concentration of purified kinase proteins (presented in µg/ml) .................................55 
Chapter 4 
Table 4-1: Kinase enzymes with their respective enzyme activity assay conditions ..................61 
Table 4-2: Reactions of kinases ................................................................................................63 
Chapter 5 
Table 5-1: Details of kinase reactions in the presence of various dilutions of plant root extract .74 
Table 5-2: Kinases and their respective IC50 values derived from the dose-response curves ....80 
 
 
 
 
 
 
 
xvi 
 
List of abbreviations 
 
A/T  Adenine Thymine 
ACT  Aspartate kinase, chorismate mutase and tyrosine A 
ADP  Adenosine diphosphate 
AIDS  Acquired Immune Deficiency Syndrome 
AK  Acetate kinase 
Amp  Ampicillin 
AMP  Adenosine MonoPhosphate  
AsK  Aspartokinase 
ATP  Adenosine triphosphate 
Bp  Base pair 
Cm  Centimetre  
CSIR  Council for Scientific and Industrial Research 
dATP  Deoxyadenosine Triphosphate  
dATP  ATP deuterated at the C8 position of the adenyl moiety 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleoside-5l-triphosphate 
E. coli  Escherichia coli 
EC  Enzyme Commission  
ECD  Enterprise Creation for Development  
EDTA  Ethylenediaminetetraacetic acid 
fwd  Forward 
g  Gram 
g  Relative centrifuge force 
gDNA  Genomic DNA 
GHMP  Galactokinase, Homoserine, Mevalonate and Phosphomevalonate kinase 
GK  Glycerol kinase 
GYT  Glycerol, yeast extract, tryptone 
HiFi  High fidelity  
His  Histidine 
HIV  Human Immunodeficiency Virus  
HPLC  High Performance Liquid Chromatography  
xvii 
 
HSK  Homoserine kinase 
IDT  Integrated DNA Technologies  
IMAC  metal ion affinity chromatography 
IPTG  Isopropyl-β-D-Thiogalactoside 
Kan  Kanamycin 
kb  Kilobase pairs  
kDa  Kilodalton 
kV  Kilovolts 
lac  Lactose 
lack  β-galactosidase 
LB  Luria Bertani broth 
LOG  Logarithm  
M  Molar 
Mbp  Mega base pairs  
MDR-TB  Multidrug-resistant Tuberculosis 
mg  Milligram 
ml  Millilitre 
mM  Millimolar 
Mtb  Mycobacterium tuberculosis 
m/v  Mass per volume  
MWCO  Molecular weight cut-off  
NaOAc  Sodium acetate 
NCBI  National Centre for Biotechnology Information 
NDK  Nucleoside diphosphokinase  
ng  Nanogram 
Ni-IDA  Nickel-iminodiacetic acid 
Ni-TED  Nickel-tris carboxymethyl ethylene diamine  
nm  Nanometers 
NMP  Nucleoside monophosphate 
NPA  Natural Products and Agroprocessing  
NTA  Nitrilotriacetic acid 
OD  Optical density 
PAGE  Polyacrylamide gel electrophoresis 
PCR  Polymerase Chain Reaction  
xviii 
 
PDB  Protein Data Bank 
pET  Plasmid expression vector T7 promoter 
pGem  Prostaglandin E2 metabolite 
pI  Isoelectric point 
P. sidoides  Pelargonium sidoides 
RBKS  Ribokinase  
RCSB  Research Collaboratory for Structural Bioinformatics 
rev  Reverse 
RNA  Ribonucleic acid  
rpm  Revolutions per minute 
Rv  Virulent  
SDS  Sodium dodecyl sulfate       
SK  Shikimate kinase 
Strep  Streptomycin 
TAE  Tris base, acetic acid and EDTA 
TB  Tuberculosis 
TDP  Thymidine diphosphate  
TGS  Tris-HCl, glycine, SDS 
ThiL  Thiamine monophosphate kinase 
TMP  Thiamine monophosphate   
Tris  Tris-hydroxymethyl-aminomethane 
U  Units 
UV  Ultra Violet 
V  Volts 
v/v  Volume per volume         
w/v  Weight per volume 
WHO  World Health Organisation  
XDR-TB  Extensively drug-resistant Tuberculosis  
X-gal  5-bromo-4-chloro-3-indolyl-b-D galactopyranoside  
°C  Degree Celsius 
µF  Microfarad 
µg  Microgram 
µl  Microlitre 
µm  Micrometre   
xix 
 
µM  Micromolar 
µMoles  Micromoles  
1 
 
Chapter 1: Introduction 
 
The 24th of March 2014, marked World TB Day, served as a day to raise awareness about the 
worldwide predicament of Tuberculosis (TB). This occasion provided a platform to discuss and 
put forward corrective actions in order to prevent the suffering that TB has brought to mankind. 
It is highly significant to address this public health crisis as TB ranks as the second leading killer 
worldwide. The objectives set out by the World Health Organisation (WHO) and Stop TB 
partnership was to find, treat and cure TB and progress towards a TB-free world (World Health 
Organisation. 2014). These goals and strategies set out can be achieved through the 
development of novel health systems and on-going TB research.  
 
 
“In the first papers concerning the aetiology of tuberculosis I have already indicated the dangers 
arising from the spread of the bacilli-containing excretions of consumptives, and have urged 
moreover that prophylactic measures should be taken against the contagious disease.” 
 
Dr Robert Koch, Nobel lecturer in Physiology/Medicine, on the struggle against 
tuberculosis (1905) 
 
“The world has made defeating AIDS a top priority. This is a blessing. But TB remains ignored. 
Today we are calling on the world to recognize that we can't fight AIDS unless we do much 
more to fight TB as well.” 
 
Nelson Mandela, Former President, on confronting the joint HIV/TB epidemics at the XV 
International Aids Conference (2004) 
 
“We’re just silently watching this epidemic unfold and spread over our eyes. TB is very clever 
because it kills you very slowly and while it’s killing you very slowly you’re walking around 
spreading it.” 
 
Dr Ruth Mcnerny, Seniour lecturer at the London School of Tropical Medicine, Director of 
TB Alert, on the global resistance to TB drugs (2013) 
 
“Too many falsely believe TB is a disease of the past, but to truly relegate this disease to the 
pages of our history books, we must identify better ways to detect and treat TB and we must 
stop the emergence of further drug resistance. TB can happen anywhere, in any community. 
Exposures can happen at school, at work, at home, while traveling, or anywhere that people are 
in close contact with one another. This is why TB prevention is a public health priority for the 
nation.” 
 
Dr. Jonathan Mermin, Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB 
Prevention on the importance of TB prevention (2014) 
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1.1  Tuberculosis (TB): A fatal disease 
 
Tuberculosis (TB) is a prevalent, and in numerous cases, fatal infectious disease that poses a 
global threat to human health (Cole et al. 1998). Infection associated with TB is second to 
HIV/AIDS as the greatest killer globally due to a single initiating infectious agent (World Health 
Organisation. 2014). 
 
Of the 9 million people a year infected with TB, 3 million are left untreated and are able to 
spread this disease even further. Many of these 3 million untreated cases are due to poverty 
and disregarded populations. Over 95% of TB cases and deaths shown in Figure 1-1 are in 
developing countries, such as South Africa, often where the percentage of AIDS is high and the 
immune systems of their populations are weak (World Health Organisation. 2014).  
 
Figure 1-1: Estimated Worlds TB incidence rates, 2012 (World Health Organisation. 2013) 
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1.2  The infectious agent: Mycobacterium tuberculosis (Mtb) 
 
Tuberculosis is caused by various strains of mycobacteria, usually Mycobacterium tuberculosis, 
and most commonly affects the lungs. It is easily transferrable from person to person through 
the air and the recipient just needs to inhale a few of these active microorganisms to become 
infected, as portrayed in Figure 1-2 (World Health Organisation. 2014). It is an obligate 
intracellular parasite that colonizes the lungs alveolar macrophages of the host’s immune 
system (Flynn & Chaney. 2003). 
 
 
Figure 1-2: Transmission and growth of Mycobacterium tuberculosis (Davis. 2007) 
 
The Mtb microorganism is an aerobic, acid-fast, bacillus, shown in Figure 1-3, with a cell wall 
which has a high lipid content (Kassim & Ray. 2004). This organism is slow-growing with a 
generation time of 24 hours in synthetic media and infected animals (Murray et al. 2005).  
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Figure 1-3: Structure of Mycobacterium tuberculosis (Microbiology In Pictures. 2013) 
 
The main feature of the organism is its intracellular pathogenesis and its ability to enter a 
dormant state. The host’s macrophages are prevented from breaking down the bacterium 
because the complex bacterial cell wall prevents the fusion of the macrophagal lysosome with 
the Mtb by blocking the bridging molecule involved in this process (Flynn & Chaney. 2003). 
Macrophage acidification and the production of reactive nitrogen intermediates are normally 
mechanisms that are employed by these specialized immune cells to kill the invading pathogen, 
but Mtb also has genes that code for the prevention of acidification of the macrophage, as well 
as the ability to neutralize reactive nitrogen intermediates (Flynn & Chaney. 2003).  
 
The host's immune responses to this organism results in the organism converting to a dormant 
stage which imitates Mtb’s metabolic shutdown, yet does not eliminate the infection. Thus, 
should the host’s immunity diminish over time, the dormant organism can be reactivated 
resulting in a lethal disease. This phenomenon of conversion from dormancy to reactivation is 
assumed to be genetically programmed and to involve intracellular signalling pathways (Cole et 
al. 1998).  
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1.3  Kinases: potential Mtb drug targets 
 
The secreted and exported Mtb proteins, in particular protein kinases, are important for 
pathogenesis and are involved in the growth of these bacteria (Tomioka. 2008). Protein kinases 
are a group of structurally distinct proteins that participate in various metabolic and signalling 
pathways (Johnson et al. 1993 and Kenyon et al. 2011). These enzymes catalyze the transfer of 
the phosphate group from high energy donor molecules such as ATP (or GTP) to a substrate. 
The substrates may be small molecules, protein or lipids which contain an alcohol, amino, 
carboxyl, or phosphate group as the phosphoryl acceptor (Kenyon et al. 2011, Cheek et al. 
2002 and Cheek et al. 2005). The phosphorylation of proteins modifies the activity of specific 
proteins which is subsequently used to control complex cellular processes. These enzymes are 
crucial for the metabolism and, hence, the survival of Mtb (Tomioka. 2008). Kinases are 
catergorised into different classes, based on their mechanism of phosphoryl transfer (Kenyon et 
al. 2012). The diversity and significance of Mtb kinases makes them an ideal object of 
biochemical research. 
 
The powerful tools of genomics, bioinformatics and genome sequencing have provided 
information about Mtb in order to facilitate the development of new therapies. The genome of 
the Mtb strain, H37Rv has been sequenced and annotated, and is deposited at NCBI as 
NC_000962.2. This is the source of all the putative gene sequences amplified here.  
 
1.3.1 Nucleoside diphosphokinase (NDK) 
 
Nucleoside diphosphokinase (NDK, EC 2.7.4.6), belongs in the family of transferases and is an 
enzyme involved in the transfer of the γ-phosphate from ATP to a nucleoside diphosphate to 
form a nucleoside triphosphate (Xu et al. 1997).  
 
nucleoside diphosphate + ATP <=> ADP + nucleoside triphosphate 
 
This reaction maintains the nucleotide pool and provides precursors for DNA and RNA 
synthesis (Sikarwar et al. 2013).  
 
The NDK enzyme is encoded by the ndkA gene and is present in almost all organisms, with 
differing oligomeric structures due to its varied functions (Sikarwar et al. 2013). This enzyme 
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has been found to play an important role in bacterial growth, signal transduction and 
pathogenicity, and mycobacterial NDK has been found to prevent phagosome maturation and 
assist in bacterial survival in the macrophage (Sikarwar et al. 2013).  
 
Dictyostelium discoideum Mtb, illustrated as a 3D structure in Figure 1-4, has been previously 
cloned through the E. coli expression system (Xu et al. 1997). The Mtb NDK has also been 
previously cloned and expressed in E. coli (Chen et al. 2002, Kumar et al. 2004) through the 
use of the H37Rv NDK gene (Rv2445c) and was identified from the annotated Mtb genome.  
 
Figure 1-4: 3D Structure of NDK from Dictyostelium discoideum. Drawn using Accelrys Discovery Studio 3.5 
(Accelrys Inc. San Diego. USA), RCSB accession number 2BEF (Xu et al.1997). 
 
1.3.2 Homoserine kinase (HSK) 
 
Homoserine kinase (HSK, EC 2.7.1.39), belongs in a large, unique class of small metabolite 
kinases, the GHMP kinase family (Zhou et al. 2000). Members in the GHMP kinase superfamily 
participate in several essential metabolic pathways, such as amino acid biosynthesis, galactose 
metabolism and the mevalonate pathway. The HSK enzyme is a catalyst for the phosphorylation 
of L-homoserine to L-homoserine phosphate, which is an intermediate in the production of L-
isoleucine and L-threonine (Krishna et al. 2001).  
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L-homoserine + ATP → O-phospho- L-homoserine + ADP 
 
This enzyme plays a vital role in threonine biosynthesis (Krishna et al. 2001). HSK is encoded 
by the thrB gene. 
 
Inactivation of the HSK activity results in threonine auxotrophy in various bacterial species and 
yeasts (Zhou et al. 2000). This means that the organism loses its ability to synthesize the 
threonine, which is essential to its growth and survival. These enzyme reactions occur 
exclusively in prokaryotes and lower eukaryotes (Rees et al. 1992). Therefore, a drug targeting 
this enzymes activity would have no effect on the host (human), making this kinase a good 
potential drug target for Mtb.  
 
Brevibacterium lactofermentum (Mateos et al. 1987) and Methanocaldococcus jannaschii (Zhou 
et al. 2000) HSK, illustrated as a 3D structure in Figure 1-5, has been previously cloned and 
expressed in E. coli. A putative H37Rv HSK gene (Rv1296) was identified in the annotated 
genome of Mtb and an amino acid sequence comparison between the two proteins indicates a 
48% identity (DNAMAN Version 5.2.10. Lynnon BioSoft). 
 
Figure 1-5: 3D Structure of HSK from Methanocaldococcus jannaschii. Drawn using Accelrys Discovery Studio 3.5 
(Accelrys Inc. San Diego. USA), RCSB accession number 1FWK (Zhou et al. 2000). 
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1.3.3 Acetate kinase (AK) 
 
Acetate kinase (AK, EC 2.7.2.1), a member of the acetokinase family, plays an important role in 
carbon cycling and energy metabolism (Boynton et al. 1996). The AK enzyme phosphorylates 
acetate to acetyl phosphate, which is subsequently converted to acetyl-CoA by 
phosphotransacetylase (Gorrell et al. 2005).  
 
Acetate + ATP → Acetyl-phosphate + ADP 
 
This enzyme is encoded by the ackA gene. Prokaryotic and eukaryotic physiology both depend 
on the metabolism of acetate, which is the production or consumption of acetyl coenzyme A 
(Latimer & Ferry. 1993). AK is a vital enzyme in bacteria as it is known to be a potential 
regulator of signal transduction pathways (Buss et al. 2001).  
 
Methanosarcina thermophile AK, illustrated as a 3D structure in Figure 1-6, has been previously 
cloned and expressed in E. coli (Gorrell et al. 2005). The putative Mtb AK gene (Rv0409) was 
identified and amino acid sequence comparison between the two proteins indicates a 41.34% 
identity (DNAMAN Version 5.2.10. Lynnon BioSoft). Other mycobacterial AKs have been 
deposited in the Protein Data Bank (www.pdb.org), with high levels of similarity to the putative 
Mtb AK (M. avum, pdb 3P4I at 74.4% and M. marinum pdb 4DQ8 at 75.1%).  
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Figure 1-6: 3D Structure of AK Methanosarcina thermophile. Drawn using Accelrys Discovery Studio 3.5 (Accelrys 
Inc. San Diego. USA), RCSB accession number 1TUY (Gorrell et al. 2005). 
 
1.3.4 Glycerol kinase (GK) 
 
Glycerol kinase (GK, EC 2.7.1.30), belongs in the carbohydrate kinase family and catalyses the 
transfer of the γ-phosphoryl of ATP to glycerol to form glycerol phosphate (Zhang et al. 2011).  
 
Glycerol + ATP → Glycerol-3-phosphate + ADP 
 
The GK enzyme is obligatory for glycerol-related metabolism pathways and the production of 
glycerol-3-phosphate which is essential for carbohydrate and fatty acid metabolism (Dipple et al. 
2001). It is encoded by the glpK gene. The enzyme activity is present widely in organisms from 
bacteria to human.  
Escherichia coli GK enzyme, illustrated as a 3D structure in Figure 1-7, has been previously 
overexpressed and purified in E. coli (Bystrom et al. 1999). The GK enzyme from Bacillus 
subtilis was also successfully expressed in E. coli (Darbon et al. 2002). A putative Mtb GK gene 
(Rv3696c) was identified and amino acid sequence comparison indicated identity of 49.8% and 
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46.6% between Mtb GK and E. coli and B. subtilis GKs, respectively (DNAMAN Version 5.2.10. 
Lynnon BioSoft).  
 
Figure 1-7: 3D Structure of GK from Escherichia coli. Drawn using Accelrys Discovery Studio 3.5 (Accelrys Inc. San 
Diego. USA), RCSB accession number 1BWF (Bystrom et al. 1999). 
 
1.3.5 Thiamine monophosphate kinase (ThiL) 
 
Thiamine monophosphate kinase (ThiL, EC 2.7.4.1), part of the transferase family, catalyzes the 
ATP–dependent phosphorylation of thiamine monophosphate to form thiamine diphosphate 
(McCulloch et al. 2008).  
 
Thiamine monophosphate + ATP → Thiamine diphosphate + ADP 
 
The ThiL enzyme is encoded by the thil gene. Thiamine metabolism is important as thiamine is 
an essential vitamin in living organisms as the active form partakes in carbohydrate metabolism 
and in the pentose phosphate pathway, where ThiL is the final enzyme in the biosynthetic 
pathway to form thiamine pyrophosphate which is the biologically active form of vitamin B. 
These enzyme reactions occur exclusively in prokaryotes, therefore a drug targeting this 
enzymes activity would have no effect on the host (human) and therefore this enzyme is a good 
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potential drug target for Mtb. The biosynthesis of the thiamine enzyme has been studied in 
prokaryotic systems both structurally and mechanistically (McCulloch et al. 2008). 
 
Aquifex aeolicus ThiL, illustrated as a 3D structure in Figure 1-8, has been previously cloned 
and expressed in E. coli (McCulloch et al. 2008). A putative H37Rv ThiL gene (Rv2977c) was 
identified and an amino acid sequence comparison between the two proteins indicates only a 
25.1% identity (DNAMAN Version 5.2.10. Lynnon BioSoft). ThiL from Methylobacillus flagellatus 
has been deposited in the Protein Data Bank (pdb 3MCQ), also with a low level of 25.4% 
similarity to the putative Mtb ThiL. 
 
Figure 1-8: 3D Structure of ThiL from Aquifex aeolicus. Drawn using Accelrys Discovery Studio 3.5 (Accelrys Inc. San 
Diego. USA), RCSB accession number 3C9T (McCulloch et al. 2008). 
 
1.3.6 Ribokinase (RBKS) 
 
Ribokinase (RBKS, EC 2.7.1.15), belongs in the pfkB family of carbohydrate kinases, also 
known as the RK family. RBKS catalyzes the phosphorylation of ribose to ribose 5-phosphate, 
in the presence of ATP and magnesium (Yang et al. 2011).  
 
D-ribose + ATP → D-ribose 5-phosphate + ADP 
12 
 
This reaction occurs during ribose metabolism. D-ribose is an important part of multiple 
biological molecules but must first be phosphorylated by RBKS to enter metabolic pathways. 
RBKS is encoded by the rbsk gene. 
 
The structure of the RBKS enzyme is conserved in several mycobacterial species which 
suggests its importance for bacterial survival. However, little is known about the function and 
regulation of this kinase. Various RBKS genes have been found in both prokaryotes and 
eukaryotes (Yang et al. 2011). The crystal structure of E. coli RBKS, illustrated as a 3D 
structure in Figure 1-9, has been previously determined (Sigrell et al. 1998). Mtb RBKS has 
been previously expressed, purified and examined for activity (Yang et al. 2011) using the 
H37Rv RBKS gene, Rv2436.  
 
Figure 1-9: 3D Structure of RBKS from Escherichia coli. Drawn using Accelrys Discovery Studio 3.5 (Accelrys Inc. 
San Diego. USA), RCSB accession number 1RKD (Sigrell et al. 1998). 
 
1.3.7 Aspartokinase (AsK) 
 
Aspartokinase (AsK, EC 2.7.2.4), belongs in the amino acid kinase family, catalyzes the 
phosphorylation of the amino acid, aspartate (Kotaka et al. 2006).  
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L-aspartate + ATP → 4-phospho-L-aspartate + ADP 
 
The AsK enzyme is encoded by the ask gene. This enzyme catalyzes an initial commitment 
step that is dependent on a feedback system that regulates the aspartate pathway, to synthesis 
certain amino acids such as lysine, threonine, methionine and isoleucine (Kotaka et al. 2006). 
Three classes of AsK’s exist based on their structure and architecture (Robin et al. 2010). 
Homo-oligomeric AsK’s are divided into either Class I or Class III, with 2 or 4 ACT domains 
respectively, and has identical subunits (Schuldt et al. 2011). Heterotetrameric AsK’s are Class 
II in which each chain contains 2 ACT domains resulting in α2β2-type AsK arranged as a dimer 
(Yoshida et al. 2010, Schuldt et al. 2011).  
 
This enzyme is present in plants and microorganisms only (Kotaka. 2006). Due to the absence 
of the aspartate pathway in higher organisms such as humans, inhibition of this kinase is a 
prospective target for a novel antibacterial drug. 
The AsK gene (Rv3709c) was identified in the annotated genome of Mtb and found to be most 
similar to the α2β2 heterotetrameric AsK from Corynebacterium glutamicum, illustrated as a 3D 
structure in Figure 1-10 (Yoshida et al. 2010, Crillo et al. 1994).  The alpha and beta subunits of 
C. glutamicum AsK have been expressed in E. coli (Yoshida et al. 2010), but only the beta 
subunit of Mtb AsK has been successfully cloned and expressed in E. coli (Schuldt et al. 2011). 
Amino acid sequence alignment of the full-length proteins (alpha subunit) of C. glutamicum and 
Mtb indicate a 71.2% identity. 
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Figure 1-10: 3D Structure of AsK from Corynebacterium glutamicum. Drawn using Accelrys Discovery Studio 3.5 
(Accelrys Inc. San Diego. USA), RCSB number 3AAW (Yoshida et al. 2010). This figure illustrates half of the enzyme 
structure with the alpha domain shown in green and the beta domain shown in purple. 
 
1.3.8 Shikimate kinase (SK) 
 
Shikimate kinase (SK, EC 2.7.1.71) is a monomeric enzyme that belongs to the nucleoside 
monophosphate (NMP) kinase structural family, where a characteristic feature of the NMP 
kinases is that they undergo large conformational changes during catalysis (Pereira et al. 2004). 
This enzyme catalyzes the phosphorylation of shikimate to shikimate 3-phosphate. 
 
Shikimate + ATP → Shikimate-3-phosphate + ADP 
 
The SK enzyme is encoded by the aroK gene and catalyzes the fifth reaction in the shikimate 
pathway, in order to generate the aromatic amino acids phenylalanine (Phe), tyrosine (Tyr), and 
tryptophan (Trp) (Pereira et al. 2004). This enzyme is present in plants and microorganisms only 
(Pereira et al. 2004) and due to the absence of this enzyme in higher organisms and the 
potential shikimate pathway targets, inhibition of this kinase is a prospective target for a novel 
antibacterial drug. 
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The Mtb SK, illustrated as a 3D structure in Figure 1-11, has been previously cloned and the 
enzyme overexpressed in soluble form in E. coli using the H37Rv gene Rv2539c (Gu et al. 
2002). The SK enzyme has been isolated, purified and functionally expressed by Kenyon et al. 
(2011), and the consequential information has been utilized, and included, in this research 
project for further tests and examination.  
 
Figure 1-11: 3D Structure of SK from Mycobacterium tuberculosis. Drawn using Accelrys Discovery Studio 3.5 
(Accelrys Inc. San Diego. USA), RCSB accession number 1L4U (Gu et al. 2002). 
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1.4  Pelargonium sidoides: a medicinal plant  
 
Pelargonium sidoides, native to South Africa, is a herbaceous perennial plant with branched 
stems arising from fleshy tuberous rhizomes (Van der Walt & Vorster. 1988). The leaves are 
borne on long petioles and the flowers have green sepals with dark maroon-red to black petals 
(Van der Walt & Vorster. 1988). This plant is widely distributed in the eastern parts of South 
Africa and in Lesotho (Dreyer & Marais. 2000). Its common names include Umckaloabo and 
South African Geranium.  
 
 
Figure 1-12: Image of Pelargonium sidoides plant (Research On Medical. 2013) 
Medicinal plants are a significant facet of the daily lives of many people and P. sidoides has 
been used as traditional medication and has a rich ethnobotanical history. Studies conducted on 
P. sidoides suggest that its roots contain compounds with antimicrobial and immunomodulating 
activity, as well as clinically proven effects on the mucociliary system and malaise (Brendler & 
Van Wyk. 2008). The tubers of this plant contain tannins, coumarins, phenolic acids and 
phenylpropanoid derivatives. The activity of the medicine prepared from this plant is partly due 
to the presence of Umckalin, as well as coumarin glycosides and sulphates (Kolodziej. 2007).  
 
Although P. sidoides has been cost effectively used to cure various disorders, there is still a lack 
of good scientific evidence available on the mode of these plants activities. Despite the 
considerable amount of clinical studies and research conducted (Kolodziej. 2011), to transform 
this traditional medicinal plant into a successful phytomedicine, there are still many unknowns in 
this field of study. Hence, it is very important to examine and further access the efficacy and 
action of this plant. 
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1.5  Research Formulation 
 
1.5.1 The Research Problem 
 
The treatment of TB is not an easy process as it involves the administration of various 
antibiotics, such as isoniazid, rifampicin, pyrazinamid, streptomycin and ethambutol, over a long 
period of time during which patients often misuse the drugs (World Health Organisation. 2014).  
 
Other challenges to effective TB treatment are its co-infection with HIV and the development of 
strains with multi-drug resistance (Yang et al. 2011). The main cause of multidrug-resistant TB 
(MDR-TB) is due to the incorrect use of anti-TB drugs or the use of low quality medication 
(World Health Organisation. 2014). Consequently, the first-line treatment has no effect on these 
resistant bacteria. This is a disadvantage, as the second line treatment is expensive, limited and 
the required chemotherapy causes critical drug reactions in patients (World Health 
Organisation. 2014). In certain exceptional cases, extensively drug-resistant TB (XDR-TB) 
develops which is usually unaffected by most treatment, including second-line medication. 
Resistant Mtb strains are present in almost all countries and this is rapidly becoming a major 
health concern (World Health Organisation. 2014). Thus, the need for new antibacterial drugs is 
evident. 
 
1.5.2 Rationale for study 
 
The identification of potential drug targets against Mtb is a crucial and on-going field of 
research. TB is curable and preventable and the vast majority of fatal cases can be eliminated 
when high-quality medication and treatment is cost effective and readily available. Hence, the 
research and discovery of novel drug targets to treat TB is highly imperative.  
 
The elimination of TB has been hindered due to the lack of understanding of the survival 
strategies used by this pathogen when in stressed environments (Yang et al. 2011). There are 
still gaps missing in this research area and there is a need to build on previous research.  
 
A group of enzymes called kinases are targeted in this study because these enzymes are 
crucial for the metabolism and, hence, the survival of Mtb. The starting point of this research 
was to target eight specific Mtb kinases. These enzymes are representatives of different classes 
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of kinases based on their mechanism of phosphoryl transfer (Kenyon et al. 2012). Due to the 
properties of the kinases as well as the nature of Mtb physiology, it was highly beneficial, at a 
preliminary phase, to isolate, purify and functionally express these kinases. This however, has 
previously been conducted for the SK enzyme, by Kenyon et al. (2011), and the resulting 
information has been used, and included, in this research project to further investigate this 
enzyme. The eukaryotic enzymes were included in this study to set a benchmark of comparison, 
to enable future work to be done. Identifying suitable enzymes within Mtb and being able to use 
them to screen against potential inhibitory compounds in P. sidoides, with the eventual goal of 
developing a drug, will contribute significantly to progress in this field of research. 
 
1.5.3 Research aims 
 
The aim of this project was to produce eight recombinant TB kinases, express them in 
Escherichia coli and purify the proteins in order to determine appropriate expression. Thereafter, 
each kinase was screened against an extract prepared from P. sidoides to identify any inhibitory 
effect in this plant extract.  
 
1.5.4 Research objectives 
 
Chapter 2: Gene Identification, Amplification and Cloning of kinases 
 To identify the putative gene sequences of the kinases using information from the 
annotated genome of Mtb and reported sequences of similar enzymes 
 To amplify such kinase genes using polymerase chain reaction (PCR) 
 To clone the PCR amplicons into vectors for expression in E. coli 
Chapter 3: E. coli Expression and Protein Purification 
 To express these genes in E. coli and develop optimal purification methods for each 
kinase 
Chapter 4: Functionality of enzymes 
 To develop and optimise validated assays to determine functionality for each kinase 
Chapter 5: Screening against Pelargonium sidoides 
 To screen each kinase against an extract prepared from P. sidoides to determine 
whether enzyme activity is inhibited by the plant extract 
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Chapter 2: Gene Identification, Amplification 
and Cloning 
 
2.1 Introduction 
 
2.1.1 Overview of objectives 
 
This chapter describes the preliminary stages of the study. The aim was to construct 
recombinant kinase expression vectors and in order to accomplish this, the use of recombinant 
DNA technology concepts, techniques and methods were applied.  
 
Firstly, the basic principles of genetic manipulation were used to identify and amplify specific 
DNA fragments from the annotated Mtb H37Rv genome. Selective amplification of the DNA 
fragments was carried out by Polymerase Chain Reactions (PCR) with the aid of polymerase 
and specific primers. The successful amplification of DNA fragments and the size of the PCR 
amplicons were determined following the analysis of electrophoresed agarose gels.   
 
Secondly, the joining of the DNA fragments into a vector, an extra chromosomal element carrier, 
was carried out. The amplified DNA fragments were cloned into Novagen vectors, via the 
pGEM®-T Easy vector, through the process of ligation. Screening and selection protocols were 
used to detect the successful cloned products. 
 
Thirdly, the recombinant DNA was transferred into a living system, a host cell, with the eventual 
goal of producing useful proteins. This was achieved by the procedures of transformation by 
electroporation.  
 
Lastly, the sequence of the insert in the expression vector was analysed and verified by 
nucleotide sequencing.  
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2.1.2 Mtb genes 
 
The complete genome sequence of the Mtb H37Rv strain has been determined and examined 
extensively to increase our understanding of this pathogen, with the intention of designing new 
therapeutic treatments. Using this annotated genome along with reported sequences for similar 
enzymes, the putative gene sequences were identified for the selected kinases (refer to Section 
1.3). 
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2.2 Materials and Methods 
 
2.2.1 Gene identification 
 
2.2.1.1 Primer design 
 
The putative kinase genes were identified in the annotated genome of H37Rv Mtb, deposited at 
NCBI as NC_000962.2. To amplify these genes, forward and reverse primers were designed 
(refer to Table 2-1). This was not done for SK, as the Mtb aroK gene was received from the 
laboratory of Chris Abell, University of Cambridge. The construct was originally obtained by 
them from AZ India. The SK work carried out has been repeated from previous work conducted 
by Kenyon et al. (2011) to be further investigated in this research study.  
 
These recombinant kinase genes were flanked by restriction endonuclease recognition 
sequences at the 5’ and 3’ ends. The PCR primers were designed such that the amplified genes 
could be cloned into a selected vector, in-frame and with a His-tag at the C- or N-terminal (refer 
to Table 2-1 and 2-2). All protein structures were checked on the Protein Data bank (PDB) for 
steric effects, to determine if the His-tag would impact on functionality. On the basis of this, the 
His-tag was either added at the C- or N-terminal. Refer to Appendix A for the His-tagged Mtb 
kinase protein sequences. 
 
The forward and reverse primers designed were analysed for specificity, internal stability and 
potential mis-priming using the software programme DNAMAN (Lynnon Biosoft). This 
programme also predicts the molecular weight and the pI of the encoded kinases (refer to Table 
2-2). The forward and reverse primers were synthesized by Integrated DNA Technologies (IDT). 
The primers were dissolved in distilled water to a final concentration of 100 µM, incubated at 
37°C to ensure a complete solution and subsequently stored at -20°C according to the 
manufacturer’s instructions. Working stocks were made to a final concentration of 2.5 µM and 
also stored at -20°C.  
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Table 2-1: Particular forward and reverse primers used to amplify specific kinase genes. Note also preferred Novagen 
vector for each construct.  
Kinase Kinase 
gene 
Forward and Reverse primers  pET vector 
 
NDK ndkA 
Rv2445c 
ndkA-Fwd  
(5'-GGCATATGACCGAACGGACTCTGGTACTG-3', NdeI recognition site 
underlined) 
ndkA-Rev  
(5'-GTGGATCCTTAGGCGCCGGGAAACCAG BamHI recognition site 
underlined) 
 
pET-16b 
HSK thrB 
Rv1296 
thrB-Fwd  
(5'-GGCATATGGTGACTCAAGCATTG-3', NdeI recognition site underlined)   
thrB-Rev  
(5'-GTCTCGAGACCGGGAACTCTTACTG-3', XhoI recognition site 
underlined) 
 
pET-20a 
 
AK ackA 
Rv0409 
ackA-Fwd  
(5'-GGCATATGGAGTAGCACCGTGCTGGTGATCAAT-3', NdeI recognition 
site underlined)  
ackA-Rev  
(5'-GTGGATCCTTACGCTCGGCGTCC-GCCCAG-3', BamHI recognition 
site underlined) 
 
pET-16b 
GK glpK 
Rv3696c 
glpK-Fwd  
(5'-GGCATATGTCCGACGCCATCCTAG-3', NdeI recognition site 
underlined) 
glpK-Rev  
(5'-CATGTCGACTTAGGACACGTCAACCCAATCC SalI recognition site 
underlined) 
 
pET-16b 
ThiL thil 
Rv2977c 
thil-Fwd 
(5’-GGTACATATGACCACTA AAGATCACTC-3’, NdeI 
Recognition site underlined) 
thil-Rev 
(5'-GATCTCGAGTTACCCTAGCGAACCTTG-3', XhoI Recognition site 
underlined) 
 
pET-28a 
RBKS rbks 
Rv2436 
rbks-Fwd 
(5'-GTACATATGGCAAACGCCAGTGAG-3', NdeI Recognition site 
underlined) 
rbks-Rev    
(5'-GATCTCGAGTTATGAACCGTTGTG-3', XhoI Recognition site 
underlined) 
 
pET-28a 
AsK ask 
Rv3709c 
ask alpha-Fwd 
(5'-GATTACATATGGCGCTCGTCGTGCAG-3', NdeI Recognition site 
underlined) 
ask alpha-Rev 
(5'-GATGTCGACTTACCGTCCCGTCCCCG-3', SalI Recognition site 
underlined) 
ask beta-Fwd 
(5'-GATCATATGGAAGACCCCATCCTGACCG-3', NdeI Recognition site 
underlined) 
ask beta-Rev 
(3’-GCCCCTGC CCTGCCCAGCTGTATG-5’,    SalI Recognition site 
underlined) 
   
CDFDuet-1 
and pET-
26a 
SK aroK 
Rv2539c 
Primers were not designed as the aroK plasmid was received from the 
laboratory of Chris Abell, University of Cambridge 
pET-15b 
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Table 2-2: Kinase genes and their relevant information 
Kinase 
gene 
C or N-terminal 
6 His-tag 
Antibiotic 
resistance and 
concentration 
used (µg/ml) 
Number of base 
pairs of gene 
insert (bp) 
Number of 
base pairs 
of insert 
plus vector 
(bp) 
Predicted 
Molecular 
weight 
(kDa) of 
kinase 
Predicted 
pI of 
kinase 
 
ndkA 
Rv2445c 
 
N-terminal 
 
Amp, 100 
 
415 
 
6114 
 
14.4 
 
6.94 
       
thrB 
Rv1296 
C-terminal Amp, 100 952 4538 33.4 5.45 
       
ackA 
Rv0409 
N-terminal Amp, 100 1162 6861 43.7 7.3 
       
glpK 
Rv3696c 
N-terminal Amp, 100 1558 7262 58.2 5.74 
       
thil 
Rv2977c 
N-terminal Kan, 50 1006 6295 36.4 5.31 
       
rbks 
Rv2436 
N-terminal Kan, 50 919 6208 32.3 6.64 
       
ask 
Rv3709c 
No His tag 
(alpha) 
C-terminal 
(beta) 
Strep, 50 (alpha) 
and Kan, 50 
(beta) 
1268 (alpha) 
and 520 (beta) 
4993 (alpha) 
and 5750 
(beta) 
44.4 (alpha)  
and 19.2 
(beta) 
4.78 
(alpha) 
and 4.89 
(beta) 
       
aroK  
Rv2539c 
 
N-terminal  Amp, 100 535 6231 20.7 11.3 
 
2.2.1.2 Authentication of template 
 
The template, H37Rv gDNA (~4.4 Mbp), was received from Ian Wiid, University of Stellenbosch. 
The concentration of the template was diluted to 100 ng/µl from its initial concentration of 540 
ng/µl and 1 µl of this was loaded onto a 0.8% [w/v] agarose gel containing ethidium bromide and 
electrophoresed according to the method of agarose gel electrophoresis described in Section 
2.2.2.2. 
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2.2.2 DNA amplification 
 
2.2.2.1 PCR Amplification 
 
The primers, indicated in Table 2-1, and the genomic DNA from Section 2.2.1.2 were used in 
PCR to amplify the DNA fragments. Note, that this was not performed for the aroK gene 
encoding SK as this was received already subcloned into a vector. All the amplification 
reactions were performed in a thermocycler, Eppendorf Mastercycler ep Gradient S PCR 
machine, in 0.2 ml PCR tubes. Various PCR parameters were tested in order to obtain optimal 
amplification. The final PCR mixtures, in a total volume of 100 µl, contained 0.42 ng/µl of the 
H37Rv template, distilled water, 1X buffer (GC+ Mg2, supplied with Taq), 0.3 mM dNTP’s, 0.3 
µM forward primer, 0.3 µM reverse primer and 1U DNA polymerase KAPA HiFi (KAPA 
Biosystems. USA). This polymerase was used as it is thermostable and generates high fidelity 
amplicons and proof reading activity (KAPA Biosystems. 2014). The PCR cycling profile 
composed of a 2 minute denaturing step at 95°C. This was then followed by 25 cycles of 
denaturation at 98°C for 20 seconds, annealing at the appropriate temperature (refer to table 2-
3) for 20 seconds and extension at 72°C for 60 seconds. A final extension of 72°C for 5 minutes 
was conducted and the PCR products were stored at 4°C.  
 
Table 2-3: Kinase genes and their specific annealing temperatures for the PCR reactions 
Kinase gene Annealing temperature (°C) 
ndkA  
Rv2445c 
 
60°C 
thrB  
Rv1296 
 
50°C 
ackA 
Rv0409 
 
50°C 
glpK 
Rv3696c 
 
50°C 
thil 
Rv2977c 
 
58°C 
rbks 
Rv2436 
 
58°C 
ask 
Rv3709c 
 
58°C 
aroK  
Rv2539c 
Not applicable 
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2.2.2.2 Agarose gel Electrophoresis 
 
In order to visualize the amplicons, an agarose gel, as described by Sambrook et al. (1989) was 
utilized. The PCR products were diluted in a 10:1 ratio, with loading dye (10% [w/v] glycerol, 
0.09% [w/v] Bromophenol blue, 0.09% [w/v] Xylene cyanol ff, 10 mM Tris pH 7.6 and 10 mM 
EDTA). These samples were analysed by loading onto an agarose gel (Saarchem-Merck. South 
Africa), containing 0.8% [w/v] agarose powder, 0.5 µg/ml ethidium bromide, in 100 ml of 1 X 
TAE buffer (40 mM Tris-HCl, 20 mM NaOAc and 1 mM EDTA; pH 8.5) and electrophoresed at 
90 volts through a 0.8% agarose gel using a Power Pac Universal™. A 1 kb DNA ladder was 
used as a standard molecular weight marker (O’Gene Ruler™, Fermentas. USA) to assess the 
size of the separated amplicon bands. The gel was viewed on a UV transilluminator, Alpha 
imager™ 3400 (Alpha Innotech), because the ethidium bromide intercalates DNA and emits 
fluorescence under UV light (Nicholl. 2008).  
 
2.2.2.3 Purification from agarose gel 
 
In order to obtain ultra-pure DNA, a clean scalpel blade was used to excise the correct DNA 
fragment from the agarose gel before the PCR products, with blunt ends, were purified from the 
agarose gel using the Zymoclean™ Gel DNA recovery kit (Zymo Research), according to the 
manufacturer’s instructions. The purity and concentrations of the eluted DNA was determined by 
running 1 µl of DNA on an agarose gel (as in Section 2.2.2.2) together with MassRuler Express 
High and Low Range markers (Fermentas. USA).  
 
2.2.3 Cloning into pGEM®-T Easy vector (Promega. USA) 
 
2.2.3.1 Insertion into pGEM®-T Easy vector (Promega. USA)  
 
The pGEM-T Easy sub-cloning technique is a common, convenient intermediate step used to 
clone PCR products (Promega. 2010). The blunt end kinase PCR products were A-tailed using 
the polymerase KAPA 2G Fast enzyme (KAPA Biosystems. USA) as it is a non-proof reading 
enzyme. This reaction mix consisted of the PCR products, 1 X 2G buffer + Mg2, 1.3 mM dATP, 
and 1 U KAPA 2G Fast enzyme. This was then incubated at 72°C for 5 minutes and then cooled 
down to 4°C for 5 minutes in the thermocycler. The kinase genes consequently contained 3’-A 
overhangs, which facilitated their A/T cloning into the suitably treated sites within the 
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commercial pGEM®-T Easy vector (refer to Appendix B for vector map) according to the 
manufacturer’s instructions (Promega. USA).  
2.2.3.2 Ligation of DNA fragments into pGEM®-T Easy vector 
 
The kinase gene PCR products were then ligated into pGEM®-T Easy vector. Ligation is the 
covalent linking of two ends of DNA with the aid of the ligase enzyme. The purified A-tailed 
kinase inserts and pGEM®-T Easy vector were combined in a molar ratio of 3:1 (vector: insert). 
The amount (ng) of insert required was determined by the equation: 
 
ng of insert= [(ng of vector X kb size of insert) / kb size of vector] X 3  
 
The ligation reactions were performed with the aid of T4 DNA ligase, according to the 
manufacturer’s instructions (Promega. USA). Each ligation reaction consisted of distilled water 
to a total volume of 10 µl, 25 ng pGEM®-T Easy vector, 1X T4 DNA ligase reaction buffer (10X 
stock), 1 U T4 DNA ligase and the 3:1 molar excess of kinase insert. The ligation reactions were 
incubated at 16°C for 16 hours and thereafter inactivated at 70°C for 15 minutes.  
 
2.2.3.3 Preparation of competent cells  
 
E. coli cells in general have to be made competent for foreign DNA uptake since these cells are 
not naturally transformable. Therefore, the preparation of electro-competent E. coli cells was 
carried out. An overnight E. coli culture was inoculated into 200 ml sterile LB broth (1% [w/v] 
NaCl, 0.5% [w/v] yeast extract and 1% [w/v] tryptone; pH 7) and incubated at 37°C until an 
OD600 of 0.6 was reached. The culture was subsequently incubated on ice for 30 minutes and 
the cells were then harvested by centrifugation at 6000 g for 10 minutes in a Sorvall RC-5B 
centrifuge. The cells were rinsed twice with 50 ml of ice-cold 10% [v/v] glycerol and suspended 
in 0.6 ml of ice-cold GYT medium (10% [v/v] glycerol, 0.125% [w/v] yeast extract, 0.25% [w/v] 
tryptone; pH 7.3). Aliquots of 80 µl of the cells were pipette into 1.5 ml Eppendorf tubes and 
stored at -70°C until further use. 
 
2.2.3.4 Electroporation and Transformation into E. coli DH10B cells   
 
Aliquots (80 µl) of competent E. coli DH10B cells were thawed on ice, and to each was added 1 
µl of the ligation mixtures containing the kinase insert and pGEM®-T Easy plasmid. This was 
27 
 
then transferred to cold electroporation cuvettes with a 0.1 cm electrode gap (Sigma-Aldrich. 
South Africa). The DNA was introduced into the electro-competent E. coli cells by 
electroporation according to the protocol described by Dower et al (1988). Briefly, the cells were 
exposed to a single electrical pulse using the Bio-Rad Gene-Pulser™ set at 1.6 kV, 25 µF and 
200 Ω. To revive the bacterial cells, this reaction mix was added to 1 ml Super Optimal 
Catabolite-repression (SOC) media (2% [w/v] tryptone, 0.5% [w/v] yeast extract, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 20 mM MgSO4 and 20 mM glucose; pH 7) for high transformation 
efficiency and incubated for 1 hour at 37°C with shaking at 200 rpm. For selection of 
recombinant clones, 200 µl aliquots of the transformed cells were spread plated on LB agar 
plates (1% [w/v] NaCl, 0.5% [w/v] yeast extract, 1% [w/v] tryptone and 1.2% [w/v] bacteriological 
agar; pH 7), 0.1 mM IPTG and 80 µg/ml X-Gal, supplemented with appropriate antibiotics (refer 
to Table 2-2) to ensure selective growth. The antibiotics were purchased from Sigma-Aldrich. 
These plates were incubated overnight at 37°C. 
 
2.2.4 Identification of successful cloned products 
 
2.2.4.1 PCR screening and inoculation  
 
The visual indication technique called blue-white screening was used. The white colonies were 
distinguished as successful cloned products and, therefore, numerous white colonies were PCR 
screened to quickly test for the presence of the desired gene, without the need to grow and 
prepare all the colonies. A few of the white colonies were resuspended in 25 µl distilled water 
and 1 µl of this suspension was added to 9 µl of the colony screen PCR reaction mix. The PCR 
reaction mix consisted of distilled water, 1X buffer, 0.2 mM dNTP’s, 0.5 µM forward primer, 0.5 
µM reverse primer and 0.02 U/µl DNA polymerase KAPA 2G Fast enzyme (KAPA Biosystems. 
USA). The polymerase KAPA 2G Fast enzyme was used as it allows for high speed and 
processing (KAPA Biosystems. 2014). This was then run on the thermocycler, with the PCR 
cycling profile composed of a 1 minute denaturing step at 95°C. This was then followed by 30 
cycles of denaturation at 95°C for 15 seconds, annealing at 50°C for 15 seconds and extension 
at 72°C for 15 seconds. A final extension of 72°C for 60 seconds was conducted and the PCR 
products were stored at 4°C. The PCR products were analysed by agarose gel electrophoresis 
(as in Section 2.2.2.2) to determine amplification at the correct sized fragments. The positive 
colonies were dotted onto LB agar plates supplemented with appropriate antibiotics and 2 
positive colonies, per kinase, were then inoculated into 5 ml LB broth supplemented with the 
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appropriate antibiotics (refer to Table 2-2) and incubated overnight at 37°C with shaking at 200 
rpm. 
2.2.4.2 Restriction enzyme digest for confirmation  
 
The plasmid DNA from the inoculated cultures was prepared using the Zyppy™ Plasmid 
Miniprep kit according to the manufacturer’s instructions (Zymo Research. USA). The eluted 
plasmid DNA was used to set up a restriction enzyme double digest according to the 
manufacturer’s instructions (Thermo Fisher Scientific Fermentas. USA). Digestion reactions 
were each set up in a total volume of 25 µl and consisted of approximately 1 to 2 µg of purified 
DNA, 0.4 U/µl of appropriate restriction endonucleases, distilled water and 1X buffer with the 
appropriate concentration of salt using the 10X buffer supplied by the manufacturer (Fermentas. 
USA) (refer to Table 2-4). The reactions were incubated for ±1 hour at 37°C and then stopped 
by adding loading dye and analysed by electrophoresis through a 0.8% agarose gel (as in 
Section 2.2.2.2) to confirm the correct sizes.  
 
Table 2-4: Kinase genes and their respective restriction enzymes and buffers used to confirm insert size 
Kinase gene Restriction enzymes 10X buffer 
 
ndkA  
Rv2445c 
 
 
BamHI and NdeI 
 
Buffer R
+ 
thrB  
Rv1296 
 
XhoI and NdeI Buffer O 
ackA 
Rv0409 
 
BamHI and NdeI Buffer R
+
 
glpK 
Rv3696c 
 
SalI and NdeI Buffer O 
thil 
Rv2977c 
 
XhoI and NdeI Buffer O 
rbks 
Rv2436 
 
XhoI and NdeI Buffer O 
ask 
Rv3709c 
 
NdeI and SalI (alpha) 
NdeI and SaII (beta) 
Buffer O 
 
aroK  
Rv2539c 
 
Not applicable Not applicable 
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2.2.4.3 Kinase insert DNA purification  
 
Following the confirmation of the correctly sized plasmid DNA from section 2.2.4.2, a large 
double digest was set up and, following digestion for 2 hours, the digestion products were run 
on an agarose gel in order to separate the kinase insert DNA from the pGEM®-T Easy vector. 
The insert was purified (as in Section 2.2.2.3) using the Zymoclean™ Gel DNA recovery kit. 
Thereafter, 1 µl of the purified kinase DNA was run on an agarose gel together with the 
Fermentas MassRuler Express High and Low Range marker to determine their concentrations 
and assess the purity of the DNA. This was subsequently stored at -20°C for use at a later 
stage.  
  
2.2.5 Cloning into selected pET vector 
 
2.2.5.1 Vector preparation 
 
Expression vectors (Novagen. Germany) (refer to Appendix B for vector maps) were selected to 
allow for in-frame fusion with the C- or N-terminal His-tag, using specific restriction sites. The 
particular vectors chosen have a lac operon system for recombinant protein expression as well 
as genes encoding antibiotic resistance (refer to Table 2-2) to ensure selective growth. The 
expression vectors were purified from inoculated vector cultures using the Zyppy™ Plasmid 
Miniprep kit. These were then double digested using the selected restriction enzymes (refer to 
Table 2-5). The use of different flanking restriction enzymes allows for immediate selection of 
correct orientation of the insert within the vector. This was then run on a 0.8% agarose gel and 
purified (as in Section 2.2.2.2 and 2.2.2.3) using the Zymoclean™ Gel DNA recovery kit 
according to the manufacturer’s instructions. Subsequently, 1 µl of the purified vector was run 
on an agarose gel together with the Fermentas MassRuler Express High and Low Range 
markers to determine their concentrations and assess the purity of the DNA. This was then 
stored at -20°C for use at a later stage. 
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Table 2-5: Kinase genes with their vectors and respective restriction enzymes and buffers used for digests  
Kinase 
gene 
Vector Restriction enzymes 10X buffer 
 
ndkA  
Rv2445c 
 
 
pET-16b 
 
BamHI and NdeI 
 
Buffer R
+ 
thrB  
Rv1296 
 
pET-20b 
 
XhoI and NdeI Buffer O 
ackA 
Rv0409 
 
pET-16b BamHI and NdeI Buffer R
+
 
glpK 
Rv3696c 
 
pET-16b XhoI and NdeI Buffer R
+
 
thil 
Rv2977c 
 
pET-28a XhoI and NdeI Buffer O 
rbks 
Rv2436 
 
pET-28a XhoI and NdeI Buffer O 
ask 
Rv3709c 
 
CDFDuet-1 (alpha)  
and pET-26a (beta) 
 
NdeI and XhoI (alpha) 
NdeI and XhoI (beta) 
Buffer O 
 
aroK  
Rv2539c 
 
Not applicable Not applicable Not applicable 
 
2.2.5.2 Ligation of kinase insert into selected vector 
 
The pure kinase inserts were ligated into the appropriate expression vector with the aid of the 
FAST-Link™ DNA ligation kit (Epicentre Technologies. USA). The 10 µl ligation reactions 
consisted of distilled water, 25 ng of the appropriate vector, 1X buffer, 0.15 U/µl DNA FAST-
Link™ ligase and kinase insert at the appropriate ratio compared to the vector. The ligation 
reactions were incubated at 16°C for 16 hours and thereafter inactivated at 70°C for 15 minutes.  
 
2.2.5.3 Transformation into E. coli DH10B cells  
 
The ligations were transformed by electroporation into E. coli DH10B cells as described in 
Section 2.2.3.4. For selection of recombinant clones, 50 µl of the bacterial cells were spread 
onto LB agar plates supplemented with appropriate antibiotic before incubating overnight at 
37°C. Random colonies were selected for PCR screening and the successful colonies were 
inoculated into 5 ml LB broth and incubated overnight at 37°C (as in Section 2.2.4.1). The 
plasmid DNA from the inoculated cultures was prepared using the Zyppy™ Plasmid Miniprep 
kit, according to the manufacturer’s instructions, and eluted in 30 µl and stored at -20°C. 
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Restriction enzyme digests (refer to Table 2-4) were performed to confirm the successful 
ligation of the kinase insert DNA in the selected vector (as in Section 2.2.4.2). Glycerol stocks 
(25% [v/v] glycerol) were made of the correctly cloned cultures and stored at -70°C. 
 
2.2.5.4 Transformation into E. coli BL21(DE3) 
 
The final host for the plasmid was E. coli BL21 (DE3), as it is well suited for high level protein 
expression. The DNA from 2.2.5.3 was electroporated (as in Section 2.2.3.4) into E. coli BL21 
(DE3) cells. For selection of recombinant clones, 50 µl of the bacterial cells were spread onto 
LB agar plates supplemented with the appropriate antibiotics (refer to Table 2-2). These plates 
were incubated overnight at 37°C. Thereafter, 2 colonies per kinase were inoculated into 5 ml 
LB broth and incubated overnight at 37°C (as in Section 2.2.4.1) and purified using the Zyppy™ 
Plasmid Miniprep kit according to the manufacturer’s instructions. Restriction enzyme digests 
were performed for confirmation (as in Section 2.2.4.2, refer to Table 2-4) and glycerol stocks 
(25% [v/v] glycerol) were made of the correctly cloned cultures and stored at -70°C. These final 
restriction enzyme digests were required for an initial screen before being sent for sequencing. 
This primary screen is to ensure that the constructs sent for sequencing, contain an insert of the 
correct size (as estimated via the agarose gel), as sequencing is costly and time-consuming.  
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Table 2-6: A list of kinase genes and their respective restriction enzymes and buffer used to confirm final digestion 
Kinase 
gene 
Restriction enzymes 10X buffer 
 
ndkA  
Rv2445c 
 
 
BamHI and NdeI 
 
Buffer R
+ 
thrB  
Rv1296 
 
XhoI and NdeI Buffer O 
ackA 
Rv0409 
 
BamHI and NdeI Buffer R
+
 
glpK 
Rv3696c 
 
BamHI and NdeI Buffer O 
thil 
Rv2977c 
 
XhoI and NdeI Buffer O 
rbks 
Rv2436 
 
XhoI and NdeI Buffer O 
ask 
Rv3709c 
 
XbaI and XhoI (alpha) 
SmaI (beta) 
Buffer Tango 
aroK  
Rv2539c 
 
Not applicable Not applicable 
 
2.2.6 Nucleotide sequencing  
 
The recombinant plasmid DNA was submitted to Inqaba Biotechnical Industries for nucleotide 
sequencing, on an Applied Biosystem® Model 3500XL automated DNA sequencer, to confirm 
the sequence of the DNA. The nucleotide sequences obtained were analysed with DNAMAN 
(Lynnon Biosoft) software for verification of the gene sequences and the in-frame fusions with 
the relevant His-tags.  
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2.3 Results and Discussion  
 
2.3.1 Template authentication  
 
A volume of 1 µl of the H37Rv template was run on a 0.8% [w/v] agarose gel as described in the 
Materials and Methods section. This was conducted in order to confirm that the DNA was not 
degraded due to the DNA being old or stored under incorrect conditions. The agarose gel, 
presented in Figure 2-1, proved that the DNA was not degraded as a tight band with not much 
smearing was observed. The size of the template DNA was significantly larger than the largest 
segment of the molecular marker ladder; however the gel was not used to quantify the DNA, but 
merely to rapidly check the quality of the template.  
 
 
 
Figure 2-1: Agarose gel electrophoresis of the H37Rv genomic DNA template. The genomic DNA was loaded onto a 
0.8% [w/v] agarose gel. M represents the molecular mass marker (O’Gene Ruler™ 1 kb DNA ladder, Fermentas. 
USA) and the sizes of this marker are indicated tto the left of the gel. The blue arrow indicates the genomic DNA 
template. 
2.3.2 DNA amplification 
 
Various PCR reactions were prepared using the H37Rv genomic DNA template and primers 
specific for the amplification of Mtb kinase gene inserts. The sizes of these inserts are shown in 
Table 2-2 above, as described in Section 2.2.2. As can be noted in Figures 2-2 and 2-3 below, 
this PCR amplification proved to be specific as DNA bands of the expected sizes were observed 
in ethidium bromide-stained agarose gels. 
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A) 
 
 
 
B) 
 
C) 
 
D) 
 
Figure 2-2: Agarose gel electrophoresis of the kinase amplicons obtained by PCR amplification using H37Rv genomic 
DNA as the template. M represents the molecular mass marker (O’Gene Ruler™ 1 kb DNA ladder, Fermentas. USA) 
and the sizes of this marker are indicated to the left of the gels. The blue arrow indicates the expected size bands in 
bp for the amplicons. A) Lane 1 represents the full length ndkA amplicon. B) Lane 1 represents the full length thrB 
amplicon. C) Lane 1 represents the full length ackA amplicon. D) Lane 1 represents the full length glpK amplicon.  
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Figure 2-3: Agarose gel electrophoresis of the kinase amplicons obtained by PCR amplification using H37Rv genomic 
DNA as the template. M represents the molecular mass marker (O’Gene Ruler™ 1 kb DNA ladder, Fermentas. USA) 
and the sizes of this marker are indicated to the left of the gels. The blue arrow indicates the expected size bands in 
bp for the amplicons. A) Lane 1 represents the full length thil amplicon. B) Lane 1 represents the full length rbks 
amplicon. C) Lane 1 represents the full length ask alpha amplicon and lane 2 represents the full length ask beta 
amplicon.  
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The challenges in gaining optimal amplification were overcome by adjusting annealing 
temperatures. Amplicons were subjected to gel purifications and thereafter the purified DNA 
was run on agarose gels together with mass rulers (data not shown) to estimate the DNA 
concentration for subsequent ligations into vectors as well as to to visualize the integrity of the 
eluted DNA.  
 
2.3.3 Plasmid construction 
 
Kinase gene DNA was first inserted into the pGEM®-T Easy vector system plasmids as 
described in the Materials and Methods section. The pGEM-T Easy sub-cloning technique 
proved to be a convenient intermediate step, as it successfully cloned the PCR products 
(Promega. 2010). The blue-white screening method proved to be effective since it involved the 
insertional inactivation of the lac gene in the presence of the insert which resulted in the 
formation of white colonies. The lac gene encodes for the enzyme β-galactosidase and when 
there is no insert, β-galactosidase uses X-gal as a synthetic product and IPTG as an inducer 
and results in the formation of blue colonies. Hence, the white colonies were representatives of 
positive clones.  
 
The kinase gene DNA that was amplified from H37Rv was cloned into suitable pET vectors 
(refer to Appendix B). The kinase genes were flanked by restriction endonuclease recognition 
sequences at the 5’ and 3’ ends. The genes cloned into its suitable vector, were in-frame with a 
His-tag at the C- or N-terminal. The complete correct plasmid diagrams are presented in Figures 
2-4 and 2-5.  
 
The strong promoter and T7 RNA polymerase favoured the production of the recombinant 
proteins as described in the following chapters.  
 
The plasmids were verified firstly by PCR amplification of the specific desired gene fragment (as 
in Section 2.3.2) and secondly by restriction enzyme digestion (refer to Section 2.3.5). The 
exact amplicons, as well as the accurate digestion fragments were obtained for all plasmids.  
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A)
ndk-pET16b
6114bp
T7t
ndk
6His
T7p
ori lacI
AmpR
ClaI (24)
HindIII (29) EcoRV (187)
BamHI (319)
XbaI (407)
PstI (629)
NdeI (734)
NcoI (795)
XbaI (834)
BglII (900)
MluI (1622)
EcoRV (2072)
XmnI (3784)
PstI (5364)
XmnI (5718)
EcoRI (6112)
 
B) 
thrB-pET20b
4538bp
T7t
6His
thrB
T7p
pBR322 ori
AmpR
f1 ori
XhoI (158)
XmnI (353)
BglII (402)
SalI (534)
EcoRV (574)
NdeI (1110)
XbaI (1148)
BglII (1206)
XmnI (1818)
PvuII (1851)
PstI (3398)
PvuI (3523)
XmnI (3752)
 
 
 
C) 
ackA-pET16b
6861bp
T7t
ackA
6His
T7p
lacI
ori
AmpR
ClaI (24)
HindIII (29)
EcoRV (187)
BamHI (319)
MluI (504)
ClaI (732)
HindIII (1192)
PstI (1292)
NdeI (1481)
NcoI (1542)
XbaI (1581)
BglII (1647)
MluI (2369)
EcoRV (2819)
XmnI (4531)
PstI (6111)
XmnI (6465)
EcoRI (6859)
 
 
D) 
glpK-pET16b
7262bp
T7t
glpK
6His
T7p
lacI
ori
AmpR
ClaI (24)
HindIII (29)
EcoRV (187)
BamHI (319)
PstI (625)
NcoI (647)
NcoI (1085)
XbaI (1258)
BamHI (1418)
PstI (1429)
BglII (1694)
XhoI (1749)
NdeI (1882)
NcoI (1943)
XbaI (1982)
BglII (2048)
MluI (2770)
EcoRV (3220)
XmnI (4932)
PstI (6512)
XmnI (6866)
EcoRI (7260)
[XhoI/SalI] (324)
 
Figure 2-4: Complete plasmid maps. (A) ndkA-pET16b, containing the ndkA gene Rv2445c in-frame with a N-terminal 
His-tag. (B) thrB-pET20, containing the Mtb putative thrB gene Rv1296 in-frame with a C-terminal His-tag. (C) ackA-
pET16b, containing the Mtb putative ackA gene Rv0409 in-frame with a N-terminal His-tag. (D) glpK-pET16b, 
containing the Mtb putative glpK gene Rv3696 in-frame with a N-terminal His-tag.  
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A)
ThiL-pET28a
6295bp
T7p
His
T7t
ThiL
lacI
pBR322 ori
Kan
f1 ori
AvaI (158)
XhoI (158)
SalI (236)
NotI (382)
ClaI (495)
NotI (523)
SalI (806)
PvuI (919)
SalI (945)
SalI (990)
AvaI (1046)
PstI (1122)
NdeI (1164)
NcoI (1222)
XbaI (1261)
BglII (1327)
MluI (2049)
EcoRV (2499)
BglI (3113)
ClaI (5043)
AvaI (5224)
PvuI (5352)
 
B) 
RK-pET28a
6208bp
T7p
His
RK
T7t
lacI
pBR322 ori
Kan
f1 ori
AvaI (158)
XhoI (158)
ClaI (201)PvuI (205)
KpnI (400)
BglI (600)
BglI (612)
KpnI (688)
BglI (915)
AvaI (1033)
NcoI (1042)
NdeI (1077)
NcoI (1135)
XbaI (1174)
BglII (1240)
MluI (1962)
EcoRV (2412)
BglI (3026)
ClaI (4956)
AvaI (5137)
PvuI (5265)
 
C)
AskAlpha-pCDFDuet-1
4993bp
T7p1
T7p2
AskAlpha
Strep
CDF ori
lacI
MCS1
N
c
oI
 (
6
9
)
B
a
m
H
I 
(1
06
)
E
c
oR
I 
(1
1
2)
P
s
tI 
(1
3
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)
S
a
lI 
(1
3
7
)
H
in
d
II
I 
(1
4
3)
N
o
tI 
(1
5
0
)
A
fl
II 
(1
6
3
)
NdeI (298)
BamHI (327)
XmnI (352)
NcoI (424)
NcoI (544)
BglI (656)
BglI (754)
NcoI (778)
BglII (811)
XhoI (903)
ClaI (1029)
NcoI (1045)
SmaI (1127)
PstI (1192)
PvuII (1310)
SmaI (1373)
AvrII (1645)
BglI (2055)
PvuI (2305)
XbaI (3578)
PvuII (3809)
PvuII (3902)
MluI (4498)
[XhoI/SalI] (1566)
 
D) 
AskBeta-pET26
5750bp
T7p
AskBeta
T7t His
lacI
pBR322 ori
Kan
F1 ori
BglI (2568)
AvaI (350)SmaI (352)
PstI (537)
AvaI (4679)
AvaI (596)
SmaI (598)
NdeI (678)
XbaI (716)
BglII (782)
SmaI (4681)
PvuI (4807)
MluI (1504)
ClaI (4498)
EcoRV (1954)
[SalI/XhoI] (158)
 
Figure 2-5: Complete plasmids maps. (A) thil-pET28a, containing the Mtb putative thil gene Rv2977c in-frame with a 
N-terminal His-tag. (B) rbks-pET28a, containing the Mtb putative rbks gene Rv2436 in-frame with a N-terminal His-
tag. (C) ask alpha-CDFDuet-1, containing the Mtb putative ask alpha gene Rv3709c with no His-tag. (D) ask beta-
pET26, containing the Mtb putative ask beta gene Rv3709c in-frame with a C-terminal His-tag. 
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2.3.4 E. coli Transformations   
 
E. coli DH10B competent cells were used as an initial host system throughout the cloning 
procedures to produce high copy numbers, but E. coli BL21 (DE3) was used thereafter as the 
final expression host for the plasmid as it is well suited and specific for high level protein 
expression. Throughout the cloning process, the identification of recombinant clones were 
performed using quick colony PCR screens and only the successful clones, represented by the 
correct band corresponding to the kinase insert genes, were selected for further procedures. 
The successful positive recombinants were established by restriction enzyme digestions (refer 
to Section 2.3.5).  
 
2.3.5 Restriction enzyme digests gels 
 
Digestions were carried out using the appropriate restriction enzymes that flanked the inserts 
(refer to Section 2.3.3 for the plasmid maps). The results in Figures 2-6 and 2-7 display the 
correct expected digest sizes on the 0.8% [w/v] agarose gels.  
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B) 
 
C) 
 
 
 
D) 
 
Figure 2-6: Agarose gel electrophoresis of the recombinant vector-kinase inserts eluted from agarose gels following 
restriction enzyme digestions. M represents the molecular mass marker (O’Gene Ruler™ 1 kb DNA ladder, 
Fermentas. USA) and the sizes of this marker are indicated to the left of the gels. The blue arrow indicates the 
expected size bands in bp. A) Lane 1 represents pET16b-ndkA DNA digested with NdeI and BamHI. B) Lane 1 
represents pET20-thrB DNA digested with NdeI and XhoI. C) Lane 1 represents pET16b-ackA DNA digested with 
NdeI and BamHI. D) Lane 1 represents pET16b-glpK DNA digested with NdeI and BamHI.  
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A) 
 
 
 
B) 
 
C) 
 
D) 
 
Figure 2-7: Agarose gel electrophoresis of the recombinant vector-kinase inserts following restriction enzyme 
digestions. M represents the molecular mass marker (O’Gene Ruler™ 1 kb DNA ladder, Fermentas. USA) and the 
sizes of this marker are indicated to the left of the gels. The blue arrow indicates the expected size bands in bp for the 
digestions. A) Lane 1 represents pET128a-thil DNA digested with NdeI and XhoI. B) Lane 1 represents pET28a-rbks 
DNA digested with NdeI and XhoI. C) Lane 1 represents CDFDuet-1-ask alpha DNA digested with XbaI and PstI. D) 
Lane 1 represents pET26a-ask beta DNA digested with SmaI.  
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2.3.6 Nucleotide sequencing 
  
Sequencing of the genes confirmed that they match identically to the reported Mtb H37Rv 
genome database. These sequences are indicated in Appendix A below. The fact that the 
sequences matched to the previously published results (described in Chapter 1: Section 1.3), 
confirmed the fidelity of the PCR reactions and gene manipulations carried out. This outcome 
validated the quality of the reagents as well as the methods and technologies applied, which in 
turn allowed the project to confidently progress into the next stage of research.  
 
2.4 Chapter conclusion  
 
In summation, the aims of this part of the study were to construct expression vectors containing 
the genes encoding Mtb kinases. The results presented in this chapter indicate that all kinase 
genes were successfully amplified from Mtb H37Rv genomic DNA and inserted into the chosen 
expression vectors with either a C- or N-terminal His-tag.  
 
The construction of kinase expression vectors was a preliminary requirement to accomplish the 
subsequent aims towards the eventual goal of TB drug discovery in order to combat this 
disease. The kinase expression vectors were then used to produce the kinase proteins in E. 
coli, for purification thereafter. The details regarding this are provided in the following chapter.
43 
 
Chapter 3: E. coli expression and Protein 
Purification  
 
3.1  Introduction  
 
This chapter describes the expression of cloned kinase genes in E. coli, and their purification. 
Protein purification is a sequence of processes used to isolate the protein from a complex 
mixture such as cells, tissues or organisms, and is fundamental for functional characterization 
and structure analysis.  
 
Firstly, the cultured cells containing the expressed proteins were broken down by sonication to 
release the proteins of interest into solution, and then filtered for further purification. Sonication 
is a mechanical technique that uses high frequency sound energy that disrupts the cell 
membranes to release the cellular particles for further purification. 
 
Secondly, the solution with the recombinant proteins was purified using appropriate protein 
purification techniques. Affinity chromatography was utilized, where diverse proteins interact 
differently with columns packed with various materials, and can, thus, be separated and eluted 
at different times by altering the chromatography conditions. The purification of soluble his-
tagged proteins can be automated with the use of the Bio-Rad Profinia™ System. This method 
is based on the production of an affinity tag sequence of 6 histidines into the N or C-terminal of 
the recombinant protein and the attachment of such tagged proteins in nickel-ion affinity 
columns. The Profinia™ system has convenient Ni-IDA resin-packed cartridges for the ease of 
purification of his-tagged proteins. Polyhistidine binds strongly to divalent metal ions such as 
nickel so that as a solution containing his-tagged recombinant proteins is passed through the 
column containing immobilized nickel ions, all untagged proteins pass through the column 
whereas the desired protein binds to the column and is subsequently eluted as a result of the 
addition of imidazole. The imidazole in the elution buffer competes with the polyhistidine tag for 
binding to the column, which enables the successful elution of the desired protein from the 
column.  
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Thirdly, gel electrophoresis via SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel 
electrophoresis) gels was used to visualize and analyse the purified proteins. This technique is 
based on the principle that proteins can be separated according to their size or molecular weight 
through electrophoresis. The theory of electrophoresis relies on the movement of a charged ion 
in an electric field. The proteins were denatured at 95°C for 5 minutes in a solution containing 
the detergent, SDS. In these conditions proteins were unfolded and coated with negatively 
charged SDS detergent molecules. The proteins were separated according to their molecular 
weight and shape. Each protein migrated as bands through the gel and was easily detected 
following staining with Coomassie blue dye. 
 
Fourthly, the protein eluates underwent dialysis with specific dialysis buffers that contained 
appropriate conditions in order to optimize kinase solubilisation and remove the unwanted 
imidazole. Lastly, the protein eluates were quantified in order to determine the concentration of 
protein obtained after purification.  
 
Soluble recombinant proteins were easily purified whereas the purification of insoluble 
recombinant proteins posed problems. The experimental study of insoluble proteins is generally 
a scientific challenge but many techniques are available to potentially obtain the desired protein 
from the cell pellet. Hence, the aims and objectives of this part of the study were to express the 
recombinant genes in E. coli effectively and develop optimal protein purification methods for 
each kinase. 
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3.2  Materials and Methods 
 
3.2.1 E. coli expression and cultivation by induction   
 
Scrapings from the glycerol stocks of the kinase expression vectors in E. coli BL21 (DE3) were 
inoculated into 50 ml LB broth supplemented with the appropriate antibiotic and incubated 
overnight at 37°C with shaking at 200 rpm. The glycerol stock of the AsK alpha and beta 
expression vectors was inoculated to be co-expressed. The SK work carried out here has been 
repeated from previous work conducted by Kenyon et al. (2011) for further investigation in this 
research study.  
 
Thereafter, 2.5 ml of the overnight cultures was transferred to 250 ml LB broth supplemented 
with the appropriate antibiotics and incubated at 37°C with shaking at 200 rpm. This was grown 
to an OD600 reading of approximately 0.6, measured using spectrophotometry. This culture was 
then induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated overnight 
at 28°C with shaking at 200 rpm.  
 
3.2.2 Lysis of cells by sonication  
 
Each overnight culture was placed in a centrifuge bottle and the cells were sedimented by 
centrifugation in the Sorvall RC-5B centrifuge at 4 080 g for 10 minutes at 4°C. The biomass 
pellets was then resuspended in 20 ml of 1X binding buffer (1 M NaCl, 20 mM Tris-HCl and 5 
mM Imidazole: pH 7.9) and sonicated using a Vibra cell sonicator for 15 minutes on a 100% 
duty cycle, separated by rest periods of 5 minutes on ice after every 5 minutes of sonication. 
Samples of 2 ml were collected and centrifuged in the Hettich Mikro 120 centrifuge at 4 080 g 
for 2 minutes at 4°C to recover the cell free extracts (supernatant) and the pellets, containing 
insoluble proteins and cell debris. The pellets were then resuspended in 2 ml of 1X binding 
buffer. The remaining culture was centrifuged at 16 300 g for 20 minutes at 4°C and stored at -
20°C.   
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3.2.3 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) analysis 
 
An SDS-PAGE (Sigma-Aldrich. USA) gel was utilized to analyse the proteins. Samples of 10 µl 
of the cell free extracts as well as resuspended pellets from section 3.2.2 were mixed with an 
equal volume of 2X protein solvent buffer (2.5% [w/v] SDS, 10% [v/v] glycerol, 5% [v/v] 2-
mercaptoethanol, 0.01% [w/v] bromophenol blue, 62.5 mM Tris; pH 6.8) and then denatured for 
5 minutes at 95°C. The SDS-PAGE gels (sized 10 cm X 8 cm X 0.5 mm) were made up of a 4% 
[w/v] acrylamide/bisacrylamide stacking gel (pH 6.8) loaded over a 10% [w/v] 
acrylamide/bisacrylamide separating gel (pH 8.8). Then 10 µl of the denatured samples were 
loaded on the SDS-PAGE gels and resolved by electrophoresis in a discontinuous gel system, 
as described by Laemmli (1970). The electrophoresis was performed in a Mini-PROTEAN® 
Tetra Cell system (Bio-Rad. USA) at 100 volts for ±1 hour in a 1X TGS electrophoresis buffer 
(0.192 M glycine, 0.1% [w/v] SDS, 0.025 M Tris-HCl; pH 8.3). Following electrophoresis, the 
gels were stained by gently rotating in a solution containing 0.125% [w/v] Coomassie brilliant 
blue G-250, 50% [v/v] methanol, 10% [w/v] acetic acid and distilled water for 30 minutes. The 
gels were then destained in a solution containing 25% [v/v] methanol, 10% [v/v] glacial acetic 
acid and distilled water, until the protein bands were visible. The staining method depends on 
the reversible binding by the proteins by a coloured chemical (Fernandez-Patron et al. 1995). 
The gels were scanned electronically on the Bio-Rad Chemidoc gel imaging system. The sizes 
of the resolved proteins were estimated by comparison to a readily available molecular mass 
marker (PageRuler™ Plus Pre-stained Protein Ladder, Fermentas. USA) that was 
simultaneously run on the gel.  
 
3.2.4 Protein Purification 
 
Depending on the results of the SDS-PAGE gels from 3.2.3, the kinase proteins were 
determined to be either soluble or insoluble (refer to Table 3-1). NDK, ThiL, RBKS, AsK and SK 
were soluble, whereas HSK, AK and GK were insoluble. The soluble proteins were purified 
through the Profinia™ System (refer to section 3.2.4.1), whereas the proteins that were 
insoluble were further treated with the intention to convert the protein from insoluble to soluble 
or to retrieve the insoluble protein effectively.  
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Table 3-1: Recommended purification method according to kinase solubility 
Kinases 
NDK HSK AK GK ThiL RBKS AsK SK 
 
Soluble 
 
 
Insoluble 
 
Insoluble 
 
Insoluble 
 
Soluble 
 
Soluble 
 
Soluble 
 
Soluble 
Profinia™ 
System 
Solubility 
studies 
& 
Denature 
& 
AKTA  
Ni-IDA  
Purification  
Solubility 
studies 
& 
Denature 
& 
MagReSyn 
Purification  
Solubility 
studies 
& 
Denature 
& 
MagReSyn 
Purification  
Profinia™ 
System  
Profinia™ 
System  
Profinia™ 
System  
Profinia™ 
System  
  
3.2.4.1 Purification of soluble his-tagged proteins using the automated Bio-Rad Profinia™   
System  
 
Each of the cell free extracts of the soluble kinases (from section 3.2.2) was filtered through a 
0.45 µm syringe filter to remove any particles present. The cell free extract was loaded onto the 
Bio-Rad Profinia™ System with appropriate buffers and reagents (refer to Appendix C) and a 1 
ml column containing nickel-iminodiacetic acid (Ni-IDA) resin. The Standard Native conditions 
and protocols were followed according to the manufacturer’s instructions (Bio-Rad. USA). This 
system purified the proteins on the basis of immobilized metal ion affinity chromatography 
(IMAC) technology by using IDA resin packed cartridges available for his-tagged proteins. The 
fraction lines collected the flowthrough, wash 1, wash 2 and elution fractions. The insoluble 
particles (pellets) and the soluble cell free extracts (supernatants) obtained after sonication and 
centrifugation in Section 3.2.2, as well as the fractions obtained from the Profinia column were 
analysed by SDS-PAGE gels as described in Section 3.2.3 and the elution fraction was dialysed 
overnight in dialysis buffer (refer to Section 3.2.5).  
 
3.2.4.2 Solubility studies 
 
Protein solubility studies were conducted for the insoluble HSK, AK and GK kinases by using 
different buffers at a variety of pH’s to determine the optimal purification buffer. Other 
purification methods that were tested included the use of and transformation of Origami (DE3) 
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competent cells instead of BL21 (DE3), co-expression of chaperone proteins using the 
Chaperone Plasmid Set (Clone Tech Laboratories, TaKaRa. USA) consisting of pG-KJE8, 
pGro7, pKJE7, pG-Tf2 and pTf16 plasmids for refolding assistance, and adding the dipeptide 
glycylglycine to the cell culture medium to increase the solubility of the expressed recombinant 
proteins. These protocols were all evaluated by SDS-PAGE gels as described in Section 3.2.3.  
 
3.2.4.3 Denaturation  
 
When the solubility studies indicated above indicated no increase in solubility of the expressed 
HSK, AK and GK kinases, urea denaturation of these insoluble kinases was attempted.  
 
The HSK kinase was purified using the AKTA Avant with packed Tricorn™ 5/50 columns (GE 
Healthcare Life Sciences. Italy). Then its biomass pellet was resuspended in 40 ml denaturation 
solublisation buffer (50 mM NaH2PO4, 300 mM NaCl, 8 M urea; pH 7.9) and was incubated for 2 
hours at 37°C with shaking at 50 rpm. This was then sonicated (as in section 3.2.2) and 
centrifuged in the Sorvall RC-5B centrifuge at 4 080 g for 10 minutes at 4°C. The supernatant 
was clarified through a 0.45 µm syringe filter and loaded onto a 25 ml bed volume Ni-NTA 
(nickel-nitrilotriacetic acid) column on the AKTA Avant, pre-equilibrated with denaturation 
solubilisation buffer. After loading, the column was washed with denaturation buffer. The HSK 
was refolded on the column using a linear gradient from 100% Denaturation Solublisation Buffer 
to 100% of the urea-free Lysis Equilibration Buffer (50 mM NaH2PO4, 300 mM NaCl; pH 7.9) 
before being eluted off the resin using Elution Buffer (50 mM NaH2PO4, 300 mM NaCl, and 250 
mM Imidazole; pH 8.0). The eluates were concentrated five times through a Vivaspin 10 kDa 
MWCO column by centrifugation at 4 080 g for 30 minutes at 4°C in the Sorvall RC-5B 
centrifuge.  
 
For AK and GK, the biomass pellets obtained from section 3.2.2 were resuspended in 40 ml 
denaturation lysis buffer (50 mM KH2PO4, 300 mM NaCl, 6 M urea, 5 mM Imidazole; pH 8.0) 
and sonicated (as in section 3.2.2). After centrifugation at 4 080g for 10 minutes at 4°C, the 
supernatant was clarified through a 0.45 µm syringe filter and loaded onto the Profinia™ 
System, with a 1 ml Ni-IDA cartridge, using the Denaturing IMAC protocol according to the 
manufacturer’s instructions. The denaturing Elution Buffer contained 50 mM KH2PO4, 300 mM 
NaCl, 3 M urea, 250 mM Imidazole at pH 8.0. Matrix-assisted refolding techniques as described 
for HSK and the Protino® Ni-TED and Ni-IDA (Macherey-Nagel) drip columns with buffers were 
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also tested, according to the manufacturer’s instructions (Macherey-Nagel. Germany). Samples 
were analysed by SDS-PAGE gels and the eluates were dialysed overnight (refer to section 
3.2.5).  
 
3.2.4.4 MagReSyn™ NTA Purification  
 
The denaturation of AK and GK as described above subsequently showed that the denatured 
protein precipitated during dialysis, and that the enzymes were not functional. Therefore, the 
native MagReSyn™ NTA purification method was attempted for AK and GK. MagReSyn™ is a 
magnetic microsphere support designed for Ni-affinity capture to purify and recover his-tagged 
proteins.  
 
The biomass pellets (from section 3.2.2) were resuspended in 20 ml 1X binding buffer and 
sonicated as described in section 3.2.2. The scaled-up protocol was followed and the reagents 
were used according to the manufacturer’s instructions (MagReSyn™ Biosciences. South 
Africa). Samples of the fractions were taken throughout for analysis by SDS-PAGE gels as 
described in section 3.2.3.   
 
3.2.5 Dialysis  
 
The protein eluates were placed in dialysis tubing (Pierce snakeskin 10 kDa MWCO) and the 
sealed tubing was then placed in appropriate dialysis buffers and stirred at 4°C overnight. For 
details of the dialysis buffers, please refer to Table 3-2. The selected buffers were shown to 
contain the appropriate conditions to optimize kinase solubilisation. The proteins were then 
removed from the dialysis tubing and aliquots of 55 µl were pipetted into 1.5 ml Eppendorf 
tubes. The Eppendorf tubes with the protein were placed in liquid nitrogen to snap-freeze the 
protein and subsequently stored at -70°C for further use at a later stage. The AK and GK 
kinases were not placed in liquid nitrogen to snap-freeze, but rather the aliquots of 50 µl of the 
dialysed protein were pipetted into 1.5 ml Eppendorf tubes and 50% [v/v] Glycerol-50% was 
added and subsequently stored at -70°C for use at a later stage. Samples were run on SDS-
PAGE gels to confirm the presence and size of the protein. 
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Table 3-2: Dialysis buffers used to solubilise NDK, HSK, AK, GK, ThiL, RBKS, AsK and SK kinase proteins  
A) NDK B) HSK C) AK & GK 
 
50 mM Tris pH 8.0 
100 mM KCl 
1 mM DTT 
1 mM MgCl2.6H2O 
 
50 mM MOPS pH 8.0 
150 mM NaCl 
1 mM DTT 
10 mM MgCl2.6H2O 
 
50 mM Tris pH 7.5 
150 mM NaCl 
1 mM DTT 
5 mM MgCl2.6H2O 
D) ThiL & RBKS E) AsK F) SK 
 
50 mM MOPS pH 7.6 
150 mM NaCl 
1 mM DTT 
10 mM MgCl2.6H2O 
 
50 mM Tris pH 6.0 
200 mM NaCl 
1 mM DTT 
10 mM MgCl2.6H2O 
 
 
50 mM Tris pH 7.5 
1 M NaCl 
 
3.2.6 Protein Quantitation  
 
The concentration of the protein stored at -70°C was determined using the Basic Qubit 
Fluorometric Quantitation kit as recommended by the manufacturers (Life Technologies. USA). 
This technique was based on the detection and accurate measurement of specific target 
molecules using highly sensitive fluorescence-based assays. The fluorescent dye used in the 
assays emitted signals when bound to the target protein, which minimized the effects of 
contaminants, and accurately quantified the target protein. Various dilutions of the proteins were 
added to the working solutions made up of protein buffer and Qubit fluorescent dye. These 
mixtures were thoroughly vortexed for 10 seconds before being incubated at room temperature 
for 15 minutes. The Qubit® 2.0 Fluorometer (Life Technologies. USA) was then used to 
calculate the estimated protein concentration.   
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3.3  Results and Discussion  
 
3.3.1 E. coli expression  
 
E. coli remains the favoured choice for the expression of recombinant proteins as it provides the 
simplicity of use, low cost, high speed and high level protein production. Cells such as BL21 
(DE3) were used because the pET system requires a host strain lysogenised by a DE3 phage 
segment, which encodes the T7 RNA polymerase, and regulated by the IPTG inducible lac 
promoter. The addition of IPTG at an OD600 reading of ~0.6, the mid log phase, is a crucial point 
to activate the lac operon. The cultivation and expression of the proteins was shown to be 
successful. 
 
3.3.2 Protein production evaluation  
 
The Profinia™ Protein Purification system successfully purified the NDK, ThiL, RBKS, AsK and 
SK proteins based on the principle of immobilized metal ion affinity chromatography (IMAC) 
technology. This convenient automated system was highly efficient for the purification of the his-
tagged proteins.  
 
Initial protein purification indicated that HSK, AK and GK were insoluble under native conditions.  
The incidence of insoluble proteins could be because it is a membrane-bound protein that is 
hydrophobic or misfolded when over-expressed in the host (Tripmin & Brizzard. 2009). As 
protein solubility depends on the binding buffer, different buffers with different conditions and 
modifications were tested. However, initial solubilisation experiments resulted in no major 
improvement on kinase solubility.  
 
After testing different buffers and purification methods, optimal purification of HSK, AK and GK 
kinase proteins was shown following their denaturation with urea. In addition, active HSK 
enzyme was obtained using this method, as described in the following chapter. The AKTA Avant 
was used for the on-column refolding, by gradually reducing the urea concentration from 8 M to 
0 M. This showed that it was possible to purify an insoluble recombinant protein by denaturation 
and then refolding the protein to the native conformation.  
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However, denaturation and on-column refolding did not work optimally for the AK and GK 
kinases. This could be due to incorrect folding of the protein during renaturation. The best 
results were obtained using the MagReSyn™ NTA purification method as it had an optimal 
capacity for binding of the protein and resulted in the purification of active enzyme.  
 
3.3.3 SDS-PAGE analysis of purified protein 
 
The screening of all the proteins was carried out using SDS-PAGE analysis. Protein fractions 
resulting from various stages in the purification steps are displayed in Figures 3-1 and 3-2. In 
Figures 3-1 and 3-2, the total protein is the protein fraction after sonication, prior to 
centrifugation. The insoluble protein is the pellet obtained after centrifugation which contains the 
insoluble protein and cell debris. The lane labelled loaded, is the cell free extract obtained after 
centrifugation that is loaded onto the system. The flowthrough, wash 1, wash 2 and elution 
fractions are the fraction lines collected during protein purification. Refer to Appendix C for the 
buffers and reagents used at the various stages. The presence in the eluate lane of a 
concentrated protein band of the anticipated size for each kinase indicates the successful 
purification of the kinase proteins. Contaminated proteins were present in HSK, AK, GK and 
AsK, but visual purity was estimated at 90-95%.  
 
The technique involving the use of SDS-PAGE and 10% acrylamide gels was shown to be 
successful to sequentially screen kinase purification products. This method was shown to be 
simple, effective and reproducible. 
 
Different affinity tags have different sizes and properties but ideally a tag should be small in 
order to have a negligible effect on the structure and activity of the eluted protein (Qiagen. 
2004). A 6 x His-tag has a small size of just 0.84 kDa and generally according to other studies, 
hardly ever obstructs the protein construction and function (Qiagen. 2004). Thus, using a 6 X 
His-tag was shown to be simple and suitable in the purification of the 8 kinase proteins. 
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A) 
 
 
B) 
 
 
C) 
 
 
Figure 3-1: SDS-PAGE gels of the Mtb his-tagged kinases purified from E. coli BL21 (DE3). The fractions were 
loaded on a 10% [w/v] gel. A) NDK protein fractions using the Ni-IDA resin on the Profinia™. B) HSK protein fractions 
using the Ni-IDA resin on the AKTA. C) AK and GK protein fractions using MagReSyn™.  M represents the molecular 
mass marker (PageRuler™ Plus Pre-stained Protein Ladder, Fermentas) and the sizes of this marker are indicated to 
the left of the gels. The blue arrows indicate the expected size bands in kDA for the purified protein eluates. 
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A) 
 
 
B) 
 
 
C) 
 
 
Figure 3-2: SDS-PAGE gels of the Mtb his-tagged kinases purified from E. coli BL21 (DE3). The fractions were 
loaded on a 10% [w/v] gel. A) ThiL (T) and RBKS (R) protein fractions using the Ni-IDA resin on the Profinia™. B) 
AsK protein fractions using the Ni-IDA resin on the Profinia™. C) SK protein fractions using the Ni-IDA resin on the 
Profinia™. M represents the molecular mass marker (PageRuler™ Plus Pre-stained Protein Ladder, Fermentas. 
USA) and the sizes of this marker are indicated to the left of the gels. The blue arrows indicate the expected size 
bands in kDA for the purified protein eluates.  
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3.3.4 Determination of Protein Quantitation  
 
The Qubit® 2.0 Fluorometer quantitated the purified proteins swiftly and accurately (Life 
Technologies. USA). This molecular technique provided a simple way to determine the 
concentration of the available protein for further analysis. The results are presented in Table 3-
3. The total enzyme concentration is displayed, as well as the estimated recombinant protein 
concentration by visual purity estimation.   
 
Table 3-3: Concentration of purified kinase proteins (presented in µg/ml) 
Kinase Total Enzyme Concentration 
(µg/ml) 
Estimated Recombinant protein 
concentration (µg/ml) 
 
NDK 
 
 
1480 
 
1480 
HSK 
 
935 841.5 
AK 
 
390 370.5 
GK 
 
348 330.6 
ThiL 
 
755 755 
RBKS 
 
800 800 
AsK 
 
1128 1071.6 
SK 2030 
 
2030 
 
The use of sequential purification techniques were intended to generate smaller amounts of 
purer active protein. The concentration levels of protein expression obtained through these 
sequential protein purification techniques and systems were suitable for further functional 
analysis and screening protocols.  
 
HPLC enzyme assays are routinely used as the final test for determination of the purity and 
activity of the protein. The subsequent chapter was necessary in order to determine and confirm 
if the purified protein obtained was indeed functional, and did not unfold or aggregate during the 
various purification techniques performed in this chapter.  
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3.4  Chapter conclusion  
 
In summary, the expression of the recombinant kinase genes in E. coli was successful. As 
observed, the purification of the proteins thereafter was complex, but various different methods 
and techniques were explored to obtain sufficient amounts of pure protein for further analysis.  
The purification of recombinant kinase proteins was necessary to progress towards the eventual 
detection of possible TB drug targets. The functional characterization of the purified kinases was 
then evaluated through enzyme assays. The particulars regarding this are described in the 
following chapter. 
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Chapter 4: Functional characterization of 
enzymes 
 
4.1  Introduction  
 
This research chapter describes the functional analysis of the kinases by examining the enzyme 
activity subsequent to protein purification. Enzyme activity is studied for many reasons, but in 
this area of research, the fundamental interest is for practical applications such as potential drug 
target discovery.  
 
Reaction kinetics is the general biochemical tool used to study the rates of chemical processes 
which is ultimately used to investigate molecular interactions within biological systems. More 
specifically, the basic experiment employed to study the enzyme activity during reactions is the 
measurement of the amount of substrate converted to product over time, under specific reaction 
conditions. This method of study is termed an enzyme assay. Enzymes must be assayed under 
controlled conditions because time, concentrations, pH and temperature alter the activity (Haas. 
2005). It is important to unravel the intrinsics of enzymatic chemical reactions as it can reveal 
the rates of the catalysed reactions, the specificity of the enzymes and the outcome of varying 
the conditions of the reactions (Muljadi. 2011).  
 
The survival and growth of the Mtb organism depends on complex networks of chemical 
reactions (Tomioka et al. 2008). Some of these reactions are mediated by the action of their 
kinase enzymes as described in Chapter 1. Thus, the study of the activity of the Mtb kinase 
enzymes is crucial in understanding the biochemistry of this infectious agent, as it allows us to 
study the processes within the cells of this microorganism, particularly those critical processes 
that allow the survival of these microbes.  
 
Kinases use ATP to transfer the phosphate to the protein, which implies that kinases rely mostly 
on ATP during catalysis (Kenyon et al. 2011, Cheek et al. 2002 and Cheek et al. 2005). Thus, 
the investigation to establish the effects of varying conditions of ATP concentrations on the 
enzymes activity is also essential.  
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Therefore, the aims and objectives of this section were to develop and optimize validated 
assays for the assessment of the enzymes activity in order to determine the functionality for 
each kinase, as well as to establish the reaction effects of varying concentrations of ATP.  
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4.2  Materials and Methods 
 
4.2.1 Enzyme activity analysis by High Performance Liquid Chromatography (HPLC)   
 
The kinase protein samples from the -70°C freezer were allowed to thaw on ice prior to setting 
up the enzyme High Performance Liquid Chromatography (HPLC) assays. HPLC is used to 
separate components in a mixture, to identify each component and quantify each component 
(Horvath et al. 1967). The assays performed were based on the principle of measuring the 
product formation and substrate reduction, by separation of the reaction mixture into its 
components following their movement through a HPLC column.  
 
The HPLC assay reactions were carried out in 100 µl volumes and incubated at 37°C. These 
assay reactions consisted of tubes of 90 µl of the prepared reaction mixture with either 10 µl of 
enzyme, prepared in triplicate or 10 µl distilled water, prepared in duplicate, served as a control 
blank. The reaction was then stopped with 5% [v/v] 200 mM EDTA.2Na.2H2O and subsequently 
loaded onto an Agilent 1100 HPLC to measure the adenosine diphosphate (ADP) product 
formation and the reduction of the adenosine triphosphate (ATP) substrate.  
 
All the kinases were assayed using the HPLC system which automatically injected 0.2 µl of 
each sample reaction mix onto a Phenomenex 5 μ LUNA C18 column with the mobile phase 
containing PIC A® (Waters Corporation. USA), 250 ml acetonitrile and 7 g KH2PO4 per litre of 
water. The flow rate of the mobile phase was 1 ml/minute and the separated reactants were 
detected using a UV detector to measure absorbance at a wavelength of 259 nm.  
 
An AMP, ADP and ATP standard was used to calibrate the HPLC and the levels of ADP in each 
sample were determined by using Agilent ChemStation (Revision B.02.01) software (Agilent 
Technologies. USA). The ADP blank control consisted of reactions where enzyme was 
substituted with distilled water. Absorbance values obtained for this control were subtracted 
from the enzyme reactions.   
 
Standard optimizations, not included in this dissertation, were carried out on parameters such 
as enzyme concentration, buffer, pH, salt concentration and incubation times. These enzymes 
were optimized as part of the published data (Kenyon et al. 2011 and Kenyon et al. 2012) and 
only the optimized conditions are stated. Favourable enzyme activity, in this study, was defined 
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by achieving linearity to demonstrate a constant rate, as well as attaining percentage 
conversions (of ATP to ADP) within the range of 5-15% (Wu et al. 2003). Another criterion for 
confirming favourable activity of the enzyme was to acquire data that is reproducible. ATP and 
MgCl2 concentrations were always kept at a 1:1 ratio (Walaas et al. 1962). The SK work 
performed in this chapter has been repeated from previous work conducted by Kenyon et al. 
(2011) to be further investigated in this research study.  
 
4.2.2 ATP concentration gradient assays 
 
Enzyme assays were optimised according to the deduced specific reagents and concentrations, 
with differing ATP concentration gradients as shown in Table 4-1. The incubation times 
stipulated in table 4-1 were chosen subsequent to various optimization tests conducted during 
this study.  
 
The reaction mixtures were incubated at 37°C before being stopped with the addition of a 
chelating agent - 5% [v/v] 200 mM EDTA.2Na.2H2O. An aliquot (0.2 µl) was subsequently 
loaded onto the HPLC system for measurement of ADP production. 
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Table 4-1: Kinase enzymes with their respective enzyme activity assay conditions 
Enzyme Assay reaction mixtures Incubation time  
 
NDK 
 
100 mM K-PO4 buffer (pH 6.8), 250 mM KCl 
5 nM enzyme, 0.2 M TDP 
0.25 – 1.5 mM ATP and 0.25 – 1.5 mM MgCl2 
 
 
40 minutes 
HSK 50 mM HEPES buffer (pH 7.0), 450 mM KCl 
704 nM enzyme, 10 mM Homoserine 
0.25 – 2.5 mM ATP and 0.25 – 2.5 mM MgCl2 
 
4 hours 
AK 100 mM Tris buffer (pH 7.0), 250 mM KCl 
223 nM enzyme, 10 mM Na acetate 
 0.25 – 4 mM ATP and 0.25 – 4 mM MgCl2 
 
24 hours 
GK 100 mM Tris buffer (pH 7.0), 250 mM KCl 
208.6 nM enzyme, 100 mM Glycerol 
0.25 – 2.5 mM ATP and 0.25 – 2.5 mM MgCl2 
 
24 hours 
ThiL 100 mM Tris buffer (pH 8.0), 250 mM KCl 
2074 nM enzyme, 1 mM TMP 
0.25 – 2.5 mM ATP and 0.25 – 2.5 mM MgCl2 
 
5 hours 
RBKS 100 mM Tris buffer (pH 7.2), 100 mM KCl 
250 nM enzyme, 10 mM D-ribose 
 0.25 – 4 mM ATP and 0.25 – 4 mM MgCl2 
 
4 hours 
AsK 100 mM Tris-HCl buffer (pH 7.5), 178.2 nM enzyme 
10 mM L-Aspartic acid 
0.25 – 2.5 mM ATP and 0.25 – 2.5 mM MgCl2  
 
6 hours 
SK 100 mM K-PO4 buffer (pH 6.8), 500 mM KCl 
10 nM enzyme, 8 mM shikimic acid  
0.5 – 10 mM ATP and 0.5 – 10 mM MgCl2 
20 minutes 
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4.3  Results and Discussion  
 
4.3.1 Determination of enzyme activity   
 
To evaluate the enzyme activity, the quantity of ATP converted into ADP by the action of the 
kinases was analysed. The specific substrate and product reactions measured for each kinase 
is shown in Table 4-2. The automated HPLC tool allowed for a fast analysis. This technique 
swiftly separates the components of the enzyme assay through high pressures, to identify and 
quantify each component (Horvath et al. 1967). Each component interacted slightly differently 
with the mobile phase and the Phenomenex 5 μ LUNA C18 column, which resulted in varied 
retention of the reaction mix components in the column. This is shown by different flow rates of 
reactants from the column. The quantitative analysis was examined using a sensitive UV HPLC 
detector, which generates a signal relative to the amount of sample from the output of the 
column (Horvath et al. 1967). The data were processed and displayed efficiently by the HPLC 
Agilent ChemStation (Revision B.02.01) software. The enzyme assays and HPLC analysis was 
performed and assessed in triplicate to ensure that the results were reliable.  
 
Validated assays with ideal conditions as indicated in Table 4-1 above were established in order 
to attain optimum enzyme activity for each kinase. The optimum enzyme activity was 
authenticated by the fact that the data depicted linearity on the shape of the graphs and the 
percentage conversions of ATP to ADP, calculated from the assays, were within the required 
range of 5-15% (Wu et al. 2003). The ideal conditions established and its supporting data were 
validated because the data was reproducible. These ideal conditions were then used for further 
enzyme activity analysis by ATP concentration gradient assays, which are interpreted in the 
following section.  
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Table 4-2: Reactions of kinases  
Kinase Enzyme Concentration (µg/ml) 
 
NDK 
 
 
nucleoside diphosphate + ATP <=> ADP + nucleoside triphosphate 
 
HSK 
 
L-homoserine + ATP → O-phospho- L-homoserine + ADP 
 
AK 
 
Acetate + ATP → Acetyl-phosphate + ADP 
 
GK 
 
Glycerol + ATP → Glycerol-3-phosphate + ADP 
ThiL 
 
Thiamine monophosphate + ATP → Thiamine diphosphate + ADP 
 
RBKS 
 
D-ribose + ATP → D-ribose 5-phosphate + ADP 
 
AsK 
 
L-aspartate + ATP → 4-phospho-L-aspartate + ADP 
 
SK Shikimate + ATP → Shikimate-3-phosphate + ADP 
 
 
4.3.2 ATP concentration gradient assay outcome 
 
ATP is known as the primary energy source for all living organisms (Bergman. 1999). In this 
field of enzyme research, the chemical energy available in the phosphate bond of ATP is 
required to drive the kinase-dependent phosphorylation reactions in order to modify the activity 
of specific proteins. These specific protein kinases are required to facilitate and control 
metabolic and signaling pathways (Kenyon et al. 2012). This basic chemical reaction was 
explored to deduce functionality.  
 
The dephosphorylation of ATP to produce ADP was observed immediately upon addition of the 
enzyme to the reaction mix (T0). The ADP levels measured in the blank controls (no enzyme) 
were subtracted from the final ADP concentration (absolute value) measured at the completion 
of the reaction. The resulting net ADP levels, as well as the blank ADP levels and the ADP 
levels at time zero, were plotted against the ATP concentrations with error bars. The error bars 
are as a result of the assays being done in triplicate. The results represented by line graphs are 
shown in Figure 4-1 to 4-8.  
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Figure 4-1: ADP production by His-NDK as a measure of TDP phosphorylating activity. The 40 minute assay contained 100 mM K-
PO4 buffer (pH 6.8), 250 mM KCl, 5 nM enzyme, 0.2 M TDP and 0.25 – 2.5 mM ATP and MgCl2. The net value of ADP production 
for this reaction was obtained by subtracting the corresponding blank value from the absolute value.  
 
Figure 4-2: ADP production by His-HSK as a measure of homoserine phosphorylating activity. The 4 hour assay contained 50 mM 
HEPES buffer (pH 7.0), 450 mM KCl, 704 nM enzyme, 10 mM Homoserine and 0.25 – 2.5 mM ATP and MgCl2. The net value of 
ADP production for this reaction was obtained by subtracting the corresponding blank value from the absolute value. The ADP 
levels at time zero were also plotted.  
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Figure 4-3: ADP production by His-AK as a measure of Na-acetate phosphorylating activity. The 24 hour assay contained 100 mM 
Tris buffer (pH 7.0), 250 mM KCl, 223 nM enzyme, 10 mM Na acetate and 0.25 – 4 mM ATP and MgCl2. The net value of ADP 
production for this reaction was obtained by subtracting the corresponding blank value from the absolute value. The ADP levels at 
time zero were also plotted.  
 
Figure 4-4: ADP production by His-GK as a measure of glycerol phosphorylating activity. The 24 hour assay contained 100 mM Tris 
buffer (pH 7.0), 250 mM KCl, 208.6 nM enzyme, 100 mM Glycerol and 0.25 – 2.5 mM ATP and MgCl2. The net value of ADP 
production for this reaction was obtained by subtracting the corresponding blank value from the absolute value. The ADP levels at 
time zero were also plotted.  
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Figure 4-5: ADP production by His-ThiL as a measure of TMP phosphorylating activity. The 5 hour assay contained 100 mM Tris 
buffer (pH 8.0), 250 mM KCl, 2074 nM enzyme, 1 mM TMP and 0.25 – 2.5 mM ATP and MgCl2. The net value of ADP production for 
this reaction was obtained by subtracting the corresponding blank value from the absolute value. The ADP levels at time zero were 
also plotted.  
 
Figure 4-6: ADP production by His-RBKS as a measure of D-ribose phosphorylating activity. The 4 hour assay contained 100 mM 
Tris buffer (pH 7.2), 100 mM KCl, 250 nM enzyme, 10 mM D-ribose and 0.25 – 4 mM ATP and MgCl2. The net value of ADP 
production for this reaction was obtained by subtracting the corresponding blank value from the absolute value.  
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Figure 4-7: ADP production by His-AsK as a measure of aspartate phosphorylating activity. The 6 hour assay contained 100 mM 
Tris-HCl buffer (pH 7.5), 178.2 nM enzyme, 10 mM L-Aspartic acid and 0.25 – 2.5 mM ATP and MgCl2. The net value of ADP 
production for this reaction was obtained by subtracting the corresponding blank value from the absolute value. The ADP levels at 
time zero were also plotted.  
 
Figure 4-8: ADP production by His-SK as a measure of shikimic acid phosphorylating activity. The 20 minute assay contained 100 
mM K-PO4 buffer (pH 6.8), 500 mM KCl, 10 nM enzyme, 8 mM shikimic acid and 0.5 – 10 mM ATP and MgCl2. The net value of ADP 
production for this reaction was obtained by subtracting the corresponding blank value from the absolute value.  
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From the figures above, it shows that the ADP product is produced even at low ATP 
concentrations and that there was a corresponding gradual increase in ADP concentrations in 
reactions containing sequentially higher ATP concentrations. The NDK, Ask and, to a lesser 
extent, GK enzymes were shown to be particularly active due to the relatively high starting 
concentration of ADP even at low ATP concentration. This means that NDK used ATP to 
transfer a phosphate to the TDP protein substrate. This demonstrates phosphorylating activity 
similar to previous studies conducted by Kumar et al (2004). The main function of HSK is to 
catalyze the phosphorylation of L-homoserine to L-homoserine phosphate. The results here 
confirmed this functionality, as in studies completed by Rees et al (1992). However, the ADP 
levels at time zero (T0), for HSK were high. This could perhaps be caused by the reactants in 
the assay mixture that exhibit reagent instability. The ADP levels for the blank reactions (no 
enzyme) for the NDK and HSK assays are observed to be high, and this could perhaps be due 
to autophosphorylation or a result of contaminated ATP as the concentration is increased. The 
results of the AK and GK enzyme assays showed the successful conversion of substrate to 
product which reflects the presence of activity. The activities of ThiL investigated by an enzyme 
assay confirmed the transfer of the phosphate of ATP which is essentially the conversion of 
thiamine monophosphate to thiamine diphosphate (McCulloch et al. 2008). The characterization 
of RBKS was verified by an assay that detected the transformation of D-ribose into D-ribose 5-
phosphate as per studies by Yang et al (2011), with slight modification of the assay reactants. 
The ADP formation determined by the HPLC during the AsK and SK enzyme assays provided 
evidence that the enzymes were active. The results overall indicated that the enzymes were 
indeed functional.  
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4.4  Chapter conclusion  
 
In conclusion, assays have been optimised and developed for each kinase. The objective to 
determine the enzyme functionality was achieved as it was evident that the purified proteins 
demonstrated validated enzyme activity. The ATP concentration gradient assay information was 
needed to elucidate the action of ATP on the function and regulation of the mechanisms 
involved in the phosphoryl transfer amongst the selected eight kinases.  
 
The investigation of the overall enzyme functionality of the kinases was required in order to 
further study, by comparison, the potential enzyme inhibition by the medicinal plant, 
Pelargonium sidoides, which is fully explained in Chapter 5.   
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Chapter 5: Screening of the effect of 
extracts of Pelargonium sidoides on Mtb 
kinase activity 
 
5.1  Introduction  
 
The classic treatment of TB is the administration of 4 antibiotics for 2 months, followed by 2 
antibiotics for another 4 months (World Health Organisation. 2014). During this long period of 
treatment, the waxy, hydrophobic cell wall of Mtb is able to survive against acids, detergents, 
oxidative bursts and antibiotics (Dartmouth Undergraduate Journal of Science. 2009). TB is a 
major health threat because Mtb penetrates the body’s own immune system, can survive for 
weeks outside the body, and has adaptive abilities to resist most of the standard antibiotics 
resulting in the development of multi-drug resistance, as well as co-infection with HIV patients 
(Dartmouth Undergraduate Journal of Science. 2009, Yang et al. 2011). The WHO has tried to 
execute a new system, called directly observed treatment short-course (DOTS), which monitors 
TB patients closely in order to assist in the absolute eradication of the infection as well as to 
prevent multi-drug resistance (World Health Organisation. 2008). Therefore, considering the fact 
that TB is a public health concern, it is imperative to find new effective drug compounds.  
 
The treatment of human diseases has, since the beginning of human civilization, consisted of 
the use of natural products such as plants, animals and minerals (Lahlou. 2013, Patwardhan et 
al. 2004). In particular, the use of plants has been a significant source for medical remedies. 
The widespread use of plants has, over time, led to the development of many modern medical 
therapies (Patwardhan et al. 2004). Unfortunately, research gaps still exist between traditional 
plant medication and modern pharmaceuticals. Hence, the extensive examination and analysis 
of medically valuable plants has become a vital area of research for the discovery and 
development of novel drugs in the pharmaceutical industry (Lahlou. 2013).  
 
Pelargonium sidoides has been used by traditional healers many years ago to treat coughs, 
chest problems and TB, by the administration of a concoction of the plants root (Helmstadter. 
1996). Although this medicinal plant has been extensively used and broadly researched, there is 
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still a lack of understanding of this plant’s scientific curative effect (Kayser & Kolodziej. 1995). 
The biologically active compounds from this plant, and their key targets, have not been 
thoroughly investigated. Thus, in an effort to find new lead compounds for TB treatment, the 
final stage of this study focused on the basic screening of the TB kinases against a root extract 
of P. sidoides.  
 
Firstly, harvesting and extraction methodologies were carried out on the P. sidoides plant to 
obtain crude plant extracts of the root. Secondly kinase activity was determined, in the presence 
of the P. sidoides plant extract, using the chromatography technique of HPLC to measure 
reaction analytes. The application of these two essential processes, carried out in this section of 
the study, was ultimately to evaluate and assess the possible inhibitory effect of the plant extract 
on the eight Mtb kinases, giving an indication of the presence of a possible natural plant kinase 
inhibitor. Lastly, the results obtained were plotted on graphs to obtain dose-response curves. 
Once the dose response curves were attained, the IC50, which is the half maximum inhibition 
value, was calculated as it is a quantitative measure of the effectiveness of the plant extract in 
inhibiting the kinases’ activity (Wu et al. 2003).  
 
Hence, the central objective of this last segment of research was to screen each purified Mtb 
kinase against an extract prepared from P. sidoides, to determine any inhibitory effects by the 
plant extract.  
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5.2  Materials and Methods 
 
5.2.1 Plant Harvesting and Extraction   
 
The P. sidoides fresh plant material was supplied to the Natural Plants and Agroprocessing 
(NPA) division of CSIR Biosciences from the CSIR Enterprise Creation for Development (ECD) 
division. The roots of the plant material underwent a series of plant preparation and extraction 
procedures which were carried out by the NPA staff.  
 
The plant material was ground and then extracted in 43% (m/v) ethanol in water at 60°C, 
followed by an evaporation step to remove the ethanol. The resulting powder was then freeze-
dried and the resulting refined product, of dry plant crude extract, was placed in a plastic bottle 
and subsequently stored at 4°C. These methodologies were required for the chemical 
separation of the plant substances.   
 
5.2.2 Plant inhibitory screens 
 
The eight kinases stored at -70°C were allowed to thaw on ice in order to set up plant inhibition 
screens by means of HPLC-based activity assays.  
 
Prior to the setup of the assays, stocks of the P. sidoides plant extract were prepared. The dry 
plant crude extract stored at 4°C, was weighed out in 100 mg per 1 ml of distilled water and 
stored in a sterile 2 ml microcentrifuge tube. This was then subsequently used to set up six 1 ml 
10-fold serial dilutions in distilled water, ranging from 1 x 10-5 mg/ml to 1 x 101 mg/ml, before 
being stored at -20°C.  
 
The HPLC enzyme assays were set up according to the designed and optimized validated 
assays described in Chapter 4 with the addition of varying concentrations of the P. sidoides 
plant extract. The P. sidoides dilution stocks, stored at -20°C, were used to set up the plant 
extract concentration gradient assay for each kinase. A control assay of 0 mg/ml of plant extract 
(i.e. water) was also run in parallel, in order to serve as a negative control for activity 
comparison analysis.  
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The reagents and conditions of these HPLC assay reaction mixtures are presented in Table 5-1. 
The assay reactions were each carried out in 100 µl volumes with 10 µl of the varying plant 
extract concentrations. These assay reactions consisted of tubes of 90 µl of the prepared 
reaction mixture with either 10 µl of enzyme, prepared in triplicate or 10 µl distilled water, 
prepared in duplicate, served as a control blank. These assays were allowed to incubate at 
37°C for a specific amount of time, stipulated in Table 5-1, and thereafter stopped with 5% [v/v] 
200 mM EDTA.2Na.2H2O. The reactions were subsequently loaded onto the HPLC system for 
the measurement of ADP production (as per HPLC process in section 4.2.1). The resulting data 
was then displayed by the HPLC Agilent ChemStation (Revision B.02.01) software.  
 
The resulting data displayed were then processed and thereafter plotted on graphs to obtain 
dose-response curves with error bars. The ADP values were plotted against the plant extract 
concentration gradient, ranging from 1 x 10-6 mg/ml to 1 x 100 mg/ml, represented by LOGS. 
The absolute ADP values were subtracted by the blank values (assay with no enzyme) to give 
the net value of the ADP production. The ADP levels at time zero were also plotted.  
 
The IC50 values were calculated, with the aid of GraphPad Prism 5 (GraphPad Software Inc. 
USA), from the compiled results of the dose-response curves.  
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Table 5-1: Details of kinase reactions in the presence of various dilutions of plant root extract 
Enzyme Assay reaction mixtures Incubation time  
 
NDK 
 
100 mM K-PO4 buffer (pH 6.8), 250 mM KCl 
5 nM enzyme, 0.2 M TDP 
1 mM ATP and 1 mM MgCl2 
0-1 mg/ml P. sidoides plant extract 
 
 
40 minutes 
HSK 50 mM HEPES buffer (pH 7.0), 450 mM KCl 
704 nM enzyme, 10 mM Homoserine 
1 mM ATP and 1 mM MgCl2 
0-1 mg/ml P. sidoides plant extract 
 
 
4 hours 
AK 100 mM Tris buffer (pH 7.0), 250 mM KCl 
223 nM enzyme, 10 mM Na acetate 
1 mM ATP and 1 mM MgCl2  
0-1 mg/ml P. sidoides plant extract 
 
 
24 hours 
GK 100 mM Tris buffer (pH 7.0), 250 mM KCl 
208.6 nM enzyme, 100 mM Glycerol 
1 mM ATP and 1 mM MgCl2 
0-1 mg/ml P. sidoides plant extract 
 
 
24 hours 
ThiL 100 mM Tris buffer (pH 8.0), 250 mM KCl 
2074 nM enzyme, 1 mM TMP 
1 mM ATP and 1 mM MgCl2 
0-1 mg/ml P. sidoides plant extract 
 
 
5 hours 
RBKS 100 mM Tris buffer (pH 7.2), 100 mM KCl 
250 nM enzyme, 10 mM D-ribose 
1 mM ATP and 1 mM MgCl2 
0-1 mg/ml P. sidoides plant extract 
 
 
4 hours 
AsK 100 mM Tris-HCl buffer (pH 7.5), 178.2 nM enzyme 
10 mM L-Aspartic acid 
1 mM ATP and 1 mM MgCl2  
0-1 mg/ml P. sidoides plant extract 
 
 
6 hours 
SK 100 mM K-PO4 buffer (pH 6.8), 500 mM KCl 
10 nM enzyme, 8 mM shikimic acid  
1 mM ATP and 1 mM MgCl2 
0-1 mg/ml P. sidoides plant extract 
 
20 minutes 
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5.3  Results and Discussion  
 
5.3.1 Plant material   
 
The harvesting and extraction methodologies for P. sidoides were successfully conducted by 
the NPA staff.  
 
5.3.2 Pelargonium sidoides concentration gradient assay outcome  
 
The experiment conducted was to simply observe any potential inhibition by the plant extract. 
This elemental assessment was successfully carried out by HPLC-based assays, which were 
swift and validated. As indicated above, HPLC is a widely used technique for the isolation and 
detection of biological compounds (Horvath et al. 1967). The inhibitory activity was determined 
by the measurement of the kinase enzymatic activity, in comparison to the enzymatic activity of 
the kinase exposed to the plant extract. Each assay point was conducted in triplicate in order to 
obtain reliable results.  
 
The resulting graphs of the ADP production by the kinases as a measure against a LOG 
concentration gradient of the plant extract, ranging from 1 x 10-6 – 1 x 100 mg/ml, are shown in 
Figures 5-1 to 5-8, with error bars. The error bars are as a result of the assays being done in 
triplicate. The calculated IC50 values are tabulated in Table 5-2. 
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Figure 5-1: ADP production by His-NDK as a measure against a LOG concentration gradient of P. sidoides extract. The 40 minute 
assay contained 100 mM K-PO4 buffer (pH 6.8), 250 mM KCl, 5 nM enzyme, 0.2 M TDP, 1 mM ATP, 1 mM MgCl2 and 1 x 10
-6
 
mg/ml to 1 x 10
0
 mg/ml P. sidoides plant extract. The varying concentrations of P. sidoides plant extract are represented by LOGS.  
 
Figure 5-2: ADP production by His-HSK as a measure against a LOG concentration gradient of P. sidoides extract. The 4 hour 
assay contained 50 mM HEPES buffer (pH 7.0), 450 mM KCl, 704 nM enzyme, 10 mM Homoserine and 1 mM ATP, 1 mM MgCl2 
and 1 x 10
-6
 mg/ml to 1 x 10
0
 mg/ml P. sidoides plant extract. The varying concentrations of P. sidoides plant extract are represented 
by LOGS. 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
0.12 
0.14 
0.16 
-8.0 -6.0 -4.0 -2.0 0.0 
A
D
P
 p
ro
d
u
c
e
d
 (
m
M
) 
LOG P. sidoides extract concentration 
Absolute values 
Net values 
Blank 
T0 
NDK 
-0.02 
0.00 
0.02 
0.04 
0.06 
0.08 
0.10 
0.12 
0.14 
-8.0 -6.0 -4.0 -2.0 0.0 
A
D
P
 p
ro
d
u
c
e
d
 (
m
M
) 
LOG P. sidoides extract concentration 
Absolute values 
Net values 
Blank 
T0 
HSK 
77 
 
 
Figure 5-3: AK - ADP production by His-AK as a measure against a LOG concentration gradient of P. sidoides extract. The 24 hour 
assay contained 100 mM Tris buffer (pH 7.0), 250 mM KCl, 223 nM enzyme, 10 mM Na acetate and 1 mM ATP, 1 mM MgCl2 and 1 
x 10
-6
 mg/ml to 1 x 10
0
 mg/ml P. sidoides plant extract.. The varying concentrations of P. sidoides plant extract are represented by 
LOGS.  
 
Figure 5-4: GK - ADP production by His-GK as a measure against a LOG concentration gradient of P. sidoides extract. The 24 hour 
assay contained 100 mM Tris buffer (pH 7.0), 250 mM KCl, 208.6 nM enzyme, 100 mM Glycerol and 1 mM ATP, 1 mM MgCl2 and 1 
x 10
-6
 mg/ml to 1 x 10
0
 mg/ml P. sidoides plant extract.. The varying concentrations of P. sidoides plant extract are represented by 
LOGS. 
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Figure 5-5: ADP production by His-ThiL as a measure against a LOG concentration gradient of P. sidoides extract. The 5 hour 
assay contained 100 mM Tris buffer (pH 8.0), 250 mM KCl, 2074 nM enzyme, 1 mM TMP and 1 mM ATP, 1 mM MgCl2 and 1 x 10
-6
 
mg/ml to 1 x 10
0
 mg/ml P. sidoides plant extract. The varying concentrations of P. sidoides plant extract are represented by LOGS. 
 
Figure 5-6: ADP production by His-RBKS as a measure against a LOG concentration gradient of P. sidoides extract. The 4 hour 
assay contained 100 mM Tris buffer (pH 7.2), 100 mM KCl, 250 nM enzyme, 10 mM D-ribose and 1 mM ATP, 1 mM MgCl2 and 1 x 
10
-6
 mg/ml to 1 x 10
0
 mg/ml P. sidoides plant extract. The varying concentrations of P. sidoides plant extract are represented by 
LOGS. 
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Figure 5-7: ADP production by His-AsK as a measure against a LOG concentration gradient of P. sidoides extract. The 6 hour assay 
contained 100 mM Tris-HCl buffer (pH 7.5), 178.2 nM enzyme, 10 mM L-Aspartic acid and 1 mM ATP, 1 mM MgCl2 and 1 x 10
-6
 
mg/ml to 1 x 10
0
 mg/ml P. sidoides plant extract. The varying concentrations of P. sidoides plant extract are represented by LOGS. 
 
Figure 5-8: ADP production by His-SK as a measure against a LOG concentration gradient of P. sidoides extract. The 20 minute 
assay contained 100 mM K-PO4 buffer (pH 6.8), 500 mM KCl, 10 nM enzyme, 8 mM shikimic acid and 1 mM ATP, 1 mM MgCl2 and 
and 1 x 10
-6
 mg/ml to 1 x 10
0
 mg/ml P. sidoides plant extract. The varying concentrations of P. sidoides plant extract are represented 
by LOGS. 
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Table 5-2: Kinases and their respective IC50 values derived from the dose-response curves  
Kinase IC50 value (mM) 
 
NDK 
 
 
0.00952 
HSK 
 
0.02 
AK 
 
0.01168 
GK 0.01023 
 
ThiL 
 
0.01668 
 
RBKS 
 
0.07589 
 
AsK 
 
 
0.03388 
 
SK 
 
0.001170 
 
With regard to the graphs displayed in Figure 5-1 to 5-8, it can be seen that the enzyme’s 
activity was generally constant at low levels of plant extract and then began to decrease in the 
presence of higher concentrations of plant extract. The blank and time zero values were high for 
NDK and HSK as seen in Figure 5-1 and 5-2 respectively. This is consistent with the results 
obtained from the ATP concentration gradient assay graphs in Chapter 4. At this stage, it cannot 
be certain that the inhibition displayed for HSK at the higher concentrations was caused by the 
plant only, as it could also be changes in the assay conditions which affected the activity.  
 
The IC50 values essentially represent the concentration of a drug that is required for 50% 
inhibition. The lower the IC50 value, the more potent the potential drug is. At this initial point in 
the study, the SK enzyme inhibitory assay showed the lowest IC50 value in comparison to the 
other enzymes.  
 
5.3.3 Plant inhibitory screens evaluation 
 
The data, from the biochemical analysis of the serial dilutions of P. sidoides extract, were also 
presented on bar graphs displayed in Figures 5-9 to 5-16, with error bars. These visual graphs 
were prepared to easily observe the effect of the plant extract concentration gradient, ranging 
from 0 to 1 x 100 mg/ml, on the activity of the various kinases.  
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Figure 5-9: Bar graph of ADP production by His-NDK as measured against a concentration gradient of P. sidoides 
plant extract. The varying concentrations of 0 to 1 x 10
0
 mg/ml of P. sidoides plant extract are represented by 
scientific numbers. 
 
Figure 5-10: Bar graph of ADP production by His-HSK as measured against a concentration gradient of P. sidoides 
plant extract. The varying concentrations of 0 to 1 x 10
0
 mg/ml of P. sidoides plant extract are represented by 
scientific numbers 
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Figure 5-11: Bar graph of ADP production by His-AK as measured against a concentration gradient of P. sidoides 
plant extract. The varying concentrations of 0 to 1 x 10
0
 mg/ml of P. sidoides plant extract are represented by 
scientific numbers. 
 
Figure 5-12: Bar graph of ADP production by His-GK as measured against a concentration gradient of P. sidoides 
plant extract. The varying concentrations of 0 to 1 x 10
0
 mg/ml of P. sidoides plant extract are represented by 
scientific numbers. 
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Figure 5-13: Bar graph of ADP production by His-ThiL as measured against a concentration gradient of P. sidoides 
plant extract. The varying concentrations of 0 to 1 x 10
0
 mg/ml of P. sidoides plant extract are represented by 
scientific numbers. 
 
Figure 5-14: Bar graph of ADP production by His-RBKS as measured against a concentration gradient of P. sidoides 
plant extract. The varying concentrations of 0 to 1 x 10
0
 mg/ml of P. sidoides plant extract are represented by 
scientific numbers. 
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Figure 5-15: Bar graph of ADP production by His-AsK as measured against a concentration gradient of P. sidoides 
plant extract. The varying concentrations of 0 to 1 x 10
0
 mg/ml of P. sidoides plant extract are represented by 
scientific numbers. 
 
Figure 5-16: Bar graph of ADP production by His-SK as measured against a concentration gradient of P. sidoides 
plant extract. The varying concentrations of 0 to 1 x 10
0
 mg/ml of P. sidoides plant extract are represented by 
scientific numbers. 
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The resulting data provided information regarding the inhibitory action of the P. sidoides against 
the eight kinases. The determination of plant extract-enzyme interactions was established by 
assessing the changes in the kinase activity.  
 
The results revealed in Figure 5-9 demonstrated that the NDK activity was relatively constant at 
low plant extract concentrations before starting to decrease at higher plant extract 
concentrations points of 1 x 10-2, 1 x 10-1 and 1 x 100 mg/ml. The activity of HSK and AsK was 
stable and then decreased rapidly at the last two concentration points, as seen in Figure 5-10 
and 5-15, respectively. The graph displaying the inhibitory screen results of the AK enzyme in 
Figure 5-11 does not exhibit noteworthy inhibition, as there appeared to be no significant 
reduction of activity. The GK activity portrayed in Figure 5-12 showed a gradual reduction in 
activity and then a drop in activity over the last three points. Figure 5-14, demonstrating the ADP 
production by the RBKS enzyme against the plant extract, revealed consistent activity and 
thereafter a notable decrease at the 1 X 10-1 mg/ml plant extract point until reaching a low ADP 
value at 1 x 100 mg/ml plant extract. The activity of the ThiL enzyme, presented in Figure 5-13, 
illustrates a regular reduction in ADP production and a plummet to no ADP production at all at 
the last two concentration points. Yet on the other hand, the measurement of the SK enzyme 
activity, illustrated in Figure 5-16, has reduced significantly more than the other enzymes. There 
was absolutely no activity present at the last three plant extract concentration points.  
 
This substantial ten-fold reduction of SK activity, compared to the other inhibited enzymes, 
suggests that this enzyme is a potential drug target. This notion, of SK being a potential target 
to develop antimicrobial agents, is in agreement with the authors Gu et al (2002) and Pereira et 
al (2004). This remarkable observation validates that this kinase could be a potential lead 
candidate for drug discovery.  
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5.4  Chapter conclusion  
 
In conclusion, the main intention of this study was to compare TB kinase activity under normal 
conditions alongside proteins treated with a potential inhibitor. The inhibition of the enzymes 
occurred at the higher concentrations of P. sidoides extract at a low level. However, the SK 
enzyme results presented a significantly higher inhibition and the lowest IC50 value, in 
comparison to the other kinases, which makes this kinase an attractive drug target against TB.  
 
This research conducted has increased the quality of information available in this field of study. 
These interesting results, proposing SK as a potential target, can be a starting point to extend 
this research and possibly contribute towards the discovery of curing TB. 
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Chapter 6: Concluding discussion and 
future recommendations   
 
6.1  Concluding discussion  
 
6.1.1 Insights into combating TB 
 
As previously mentioned, TB is a major health risk and the emergence of multi-drug resistance 
against existing therapeutics, as well as HIV co-infection, has become problematic (Yang et al. 
2011). TB is a disease that has the potential to be curable and preventable, provided that 
efficient medication, at a low cost, is constantly accessible for all infected patients worldwide. 
Therefore new competent TB drugs are needed immediately to treat and manage this critical 
disease. Hence, the identification of potential drug targets against Mtb is currently a crucial field 
of research.  
 
Mtb is able to establish persistent infections in the macrophage cells, which would normally be 
responsible for destroying foreign microorganisms in the body (Flynn & Chaney. 2003). This 
strategy used by Mtb makes this organism highly pathogenic and successful. The eradication of 
this disease has been stalled due to insufficient information pertaining to Mtb, and its processes 
and mechanisms (Yang et al. 2011). As a result, the complete genome sequence of the Mtb 
H37Rv strain has been established (Cole et al. 1998) to help scientists gain new insights into 
this organism at a molecular level.  
 
This research conducted, made use of the application of available genomic techniques, as well 
as systems biology, to provide further information regarding this organism, with the eventual 
goal of creating better medication to eliminate this lethal disease.  
 
6.1.2 Using kinases as potential drug targets 
 
Protein kinases are molecular switches that regulate biological functions, as they play a critical 
role in numerous metabolic and signaling pathways (Kenyon et al. 2011). Mtb kinases transmit 
signals through phosphorylation, which present many potential targets for innovative remedies 
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(Grundner et al. 2005). Therefore, the further understanding of kinases, as molecules, is 
essential in determining possible drug targets.  
 
The Mtb species differs from other bacteria, as a large proportion of its coding capacity is 
assigned to the production of enzymes (Cole et al. 1998). Mtb has a few isolated kinase and 
regulatory genes, as well as a phosphorelay system (Cole et al. 1998), which suggests that 
there is perhaps a requirement of multiple kinases at various points in Mtb metabolism.  
 
A characteristic virulent feature of Mtb is its slow growth and dormancy. The conversion from 
dormancy to reactivation is assumed to be genetically programmed and to involve intracellular 
signaling pathways (Cole et al. 1998). Given that kinases are involved in signaling, the 
inactivation of critical kinases could jeopardize these pathways, as perhaps Mtb requires back-
up kinases for critical phosphorylation reactions.  
 
The aim of this study was to firstly construct expression vectors containing the genes encoding 
Mtb kinases. The 8 kinase genes were successfully amplified from the Mtb H37Rv genomic 
DNA and inserted into selected expression vectors with a His-tag at either the C- or N-terminal. 
The reliability of the PCR reactions and gene manipulations conducted, were confirmed through 
restriction enzyme digests displayed visually on agarose gels. The accuracy of the gene 
sequences were validated by nucleotide sequencing. These authenticated results obtained, 
facilitated the progression into the next phase of study.  
 
The next objective was to express the recombinant kinase genes in E. coli for protein 
purification. The purification of the proteins was challenging, but a variety of different techniques 
were investigated in order to acquire sufficient amounts of pure protein. The resulting purified 
protein products were effectively confirmed through SDS-PAGE gels. In summation, the 
expression and purification of the recombinant kinase proteins was successfully accomplished, 
which was necessary for further analysis.  
 
HPLC enzyme assays were carried out to assess the functional characterization of the purified 
kinase proteins. Validated assays were set up and optimized for each kinase. The main 
purpose, to establish that the enzymes were indeed functional, was achieved as the proteins 
demonstrated apparent enzyme activity. The ATP concentration gradient assay results provided 
preliminary information that was required to clarify the action of ATP, as well as its role, 
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regulation and mechanism, during the phosphoryl transfer process. The overall enzyme 
functionality information was a pre-requisite for executing further plant screening comparison 
studies.  
 
6.1.3 The gap between traditional P. sidoides usage and modern pharmaceuticals  
 
The traditional use of the plant root of P. sidoides has been used to treat coughs, chest 
problems and TB. However, there is still a major research breach between traditional practice 
and modern therapies.  
 
According to the evaluation of P. sidoides antibacterial activity, conducted by Kolodziej (2007), 
the data provided positive responses from the infected cells, as oppose to the noninfected cells. 
This provided support to validate the medicinal use of P. sidoides. However, the remedial 
effects are not yet associated to biochemical defined principles and therefore further studies is 
required in order to investigate and analyse this medically significant plant (Lahlou. 2013).  
 
Other studies show that P. sidoides has a wide range of antibacterial activity on gram positive 
and gram negative organisms. Phytochemical studies show the presence of a large number of 
secondary metabolites in the plant such as tannins, coumarins, phenolic acids, phenylpropanoid 
derivatives and other chemical constituents (Brendler & Van Wyk. 2008). The exploration for the 
actual compound responsible is imperative. The main goal is to define the responsible 
antibacterial compound and recondition and enhance these activities (Taylor. 2004) for a cost-
effective remedy. 
 
The most important objective of this study was to contrast TB kinase activity under normal 
conditions against proteins treated with the possible plant inhibitor. The results revealed some 
inhibition of the enzymes only at the higher concentrations of the P. sidoides extract. P. sidoides 
exhibit remarkable diversity and complexity (Kolodziej. 2007), with broad inhibitory activity that 
perhaps promotes a general phosphorylation shut down.  
 
On the other hand, the SK enzyme results displayed a significantly higher inhibition compared to 
the other enzymes, as well as the lowest IC50 value of 0.001170. This noteworthy ten-fold 
reduction of SK activity validates and recommends that this enzyme is an attractive potential 
drug target. Another advantage is that SK, and other enzymes involved in the shikimate 
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pathway, are great potential targets for creating harmless antimicrobial agents because the 
pathway is essential for Mtb but is not present in mammals (Pereira et al. 2004). This 
perception, of SK being a lead candidate to develop antibacterial medication, has also been 
previously described by Gu et al (2002) and Pereira et al (2004).  
This study carried out has improved the value of information available in this specific field of 
study. These remarkable results, suggesting SK as a probable target, can be the starting point 
to expand this investigation further. These preliminary results could also facilitate in bridging the 
gap between traditional P. sidoides practice and modern therapies in addition to help contribute 
to the development of effective TB remedy. 
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6.2  Future recommendations  
 
The essential biologically active compound, within the P. sidoides plant extract, that is 
responsible for the inhibitory effects, is most likely concealed in the multi-component mixture. 
Thus, the separation, detection and analysis of this multi-component mixture must be carried 
out in order to utilize these natural resource compounds effectively (Lahlou. 2013).   
 
Fractionation of the plant material can be carried out, and the resulting isolated fractions can be 
tested through HPLC assays for the detection of enzyme inhibition (Tu et al. 2010). The 
fractions of the plant that demonstrate inhibitory activity can then be further dried, weighed and 
reformatted for screening. Subsequently, the evaluation of the fractions for the identification of 
the actual molecules responsible for the inhibition can be conducted. These molecules will then 
have to be purified, by using a variety of purification techniques, to further isolate these 
particular bioactive compounds for structure elucidation (Tu et al. 2010). Automated and high-
throughput methods can also be used throughout to rapidly prepare and evaluate various plant 
fractions to provide a more detailed and accurate study (Tu et al. 2010). 
 
Once these fractionation studies are established, they can be used as a platform for advanced 
studies in the pharmacological sector. Pharmacological methods can be applied for the ultimate 
production and assessment of medically effective TB drugs. This research will allow the 
development and design of novel TB drugs and as a consequence, unlock opportunities for new 
drug systems.  
  
 
 
 
 
 
 
 
 
 
 
 
92 
 
Appendices 
 
Appendix A 
 
1) Nucleoside diphosphokinase 
1         ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGT 
1          M  G  H  H  H  H  H  H  H  H  H  H  S  S  G  H  I  E  G  R  
 
61        CATATGACCGAACGGACTCTGGTACTGATCAAGCCGGATGGCATCGAAAGGCAGCTGATC 
21         H  M  T  E  R  T  L  V  L  I  K  P  D  G  I  E  R  Q  L  I   
 
121       GGCGAGATCATCAGCCGCATCGAGCGCAAAGGCCTCACCATCGCTGCGCTGCAGCTCAGG 
41         G  E  I  I  S  R  I  E  R  K  G  L  T  I  A  A  L  Q  L  R   
 
181       ACCGTCAGCGCGGAGTTGGCCAGCCAGCACTACGCCGAACATGAAGGCAAACCATTCTTT 
61         T  V  S  A  E  L  A  S  Q  H  Y  A  E  H  E  G  K  P  F  F   
 
241       GGATCGTTGCTGGAGTTCATCACGTCGGGTCCGGTGGTAGCGGCGATCGTGGAGGGAACC 
81         G  S  L  L  E  F  I  T  S  G  P  V  V  A  A  I  V  E  G  T   
 
301       CGAGCCATCGCGGCGGTTCGCCAACTCGCCGGCGGCACCGACCCGGTGCAGGCGGCGGCG 
101        R  A  I  A  A  V  R  Q  L  A  G  G  T  D  P  V  Q  A  A  A   
 
361       CCCGGCACAATCCGGGGCGACTTCGCTCTAGAGACGCAGTTCAACCTGGTGCACGGGTCT 
121        P  G  T  I  R  G  D  F  A  L  E  T  Q  F  N  L  V  H  G  S   
 
421       GATTCGGCCGAATCCGCGCAGCGCGAAATCGCGCTCTGGTTTCCCGGCGCCTAA 
141        D  S  A  E  S  A  Q  R  E  I  A  L  W  F  P  G  A  *   
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2) Homoserine kinase 
1         ATGGTGACTCAAGCATTGTTGCCTTCTGGGCTGGTGGCCAGTGCGGTGGTGGCGGCGTCC 
1          M  V  T  Q  A  L  L  P  S  G  L  V  A  S  A  V  V  A  A  S  
 
61        AGTGCAAACCTGGGCCCGGGCTTCGACAGTGTCGGTTTGGCGCTGAGTCTCTACGACGAG 
21         S  A  N  L  G  P  G  F  D  S  V  G  L  A  L  S  L  Y  D  E   
 
121       ATCATCGTCGAGACAACAGATTCCGGCTTGACGGTGACTGTAGACGGCGAGGGCGGCGAC 
41         I  I  V  E  T  T  D  S  G  L  T  V  T  V  D  G  E  G  G  D   
 
181       CAGGTGCCGCTGGGCCCCGAGCACCTCGTGGTCCGCGCCGTGCAGCACGGGTTACAGGCA 
61         Q  V  P  L  G  P  E  H  L  V  V  R  A  V  Q  H  G  L  Q  A   
 
241       GCGGGGGTCAGCGCCGCCGGCCTGGCGGTGCGCTGCCGCAACGCCATCCCGCACTCCCGC 
81         A  G  V  S  A  A  G  L  A  V  R  C  R  N  A  I  P  H  S  R   
 
301       GGCCTCGGCTCCTCCGCGGCAGCAGTTGTGGGCGGTCTTGCGGCCGTTAACGGTCTTGTC 
101        G  L  G  S  S  A  A  A  V  V  G  G  L  A  A  V  N  G  L  V   
 
361       GTACAAACGGATTCGTCACCATCGAGCGATGCTGAGCTGATTCAGTTGGCTTCGGAGTTC 
121        V  Q  T  D  S  S  P  S  S  D  A  E  L  I  Q  L  A  S  E  F   
 
421       GAGGGTCATCCCGACAACGCGGCGGCCGCGGTTTTGGGTGGTGCCGTGGTTTCGTGGACT 
141        E  G  H  P  D  N  A  A  A  A  V  L  G  G  A  V  V  S  W  T   
 
481       GACCACAGTGGTGACCGGCCCAACTATTCGGCCGTATCACTGCGGCTTCATCCCGATATC 
161        D  H  S  G  D  R  P  N  Y  S  A  V  S  L  R  L  H  P  D  I   
 
541       CGCCTGTTCACTGCGATTCCCGAGCAGCGTTCGTCGACCGCGGAAACGCGGGTGCTATTG 
181        R  L  F  T  A  I  P  E  Q  R  S  S  T  A  E  T  R  V  L  L   
 
601       CCCGCGCAGGTTAGTCACGACGACGCACGGTTCAATGTCAGTCGCGCGGCGCTGCTGGTG 
201        P  A  Q  V  S  H  D  D  A  R  F  N  V  S  R  A  A  L  L  V   
 
661       GTTGCGCTCACCGAACGGCCCGATCTGCTGATGGCGGCCACCGAAGATCTGCTTCATCAG 
221        V  A  L  T  E  R  P  D  L  L  M  A  A  T  E  D  L  L  H  Q   
 
721       CCGCAACGTGCCGCGGCAATGACAGCCTCCGCGGAATATCTTCGGCTGTTGCGGCGTCAT 
241        P  Q  R  A  A  A  M  T  A  S  A  E  Y  L  R  L  L  R  R  H   
 
781       AACGTGGCAGCAGCACTGTCCGGGGCAGGTCCTTCGTTGATCGCCCTGAGTACAGATTCA 
261        N  V  A  A  A  L  S  G  A  G  P  S  L  I  A  L  S  T  D  S   
 
841       GAGTTGCCGACCGACGCCGTGGAGTTCGGAGCCGCAAAGGGATTTGCCGTTACCGAGCTG 
281        E  L  P  T  D  A  V  E  F  G  A  A  K  G  F  A  V  T  E  L   
 
901       ACTGTTGGCGAGGCGGTTCGCTGGAGCCCGACAGTAAGAGTTCCCGGTCTCGAGCACCAC 
301        T  V  G  E  A  V  R  W  S  P  T  V  R  V  P  G  L  E  H  H   
 
961       CACCACCACCACTGA 
321        H  H  H  H  *   
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3) Acetate kinase 
1         ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGT 
1          M  G  H  H  H  H  H  H  H  H  H  H  S  S  G  H  I  E  G  R  
 
61        CATATGAGTAGCACCGTGCTGGTGATCAATTCCGGCTCGTCGTCGCTGAAGTTCCAGCTC 
21         H  M  S  S  T  V  L  V  I  N  S  G  S  S  S  L  K  F  Q  L   
 
121       GTCGAGCCGGTCGCCGGCATGTCACGTGCCGCCGGGATTGTCGAGCGGATCGGCGAGCGG 
41         V  E  P  V  A  G  M  S  R  A  A  G  I  V  E  R  I  G  E  R   
 
181       TCATCCCCGGTTGCCGATCACGCCCAGGCGCTGCATCGCGCATTCAAGATGTTGGCCGAG 
61         S  S  P  V  A  D  H  A  Q  A  L  H  R  A  F  K  M  L  A  E   
 
241       GACGGAATTGACCTGCAGACCTGCGGGCTGGTGGCGGTCGGACACCGGGTGGTCCACGGC 
81         D  G  I  D  L  Q  T  C  G  L  V  A  V  G  H  R  V  V  H  G   
 
301       GGCACGGAGTTTCACCAGCCGACGCTGCTGGATGACACGGTGATCGGCAAGCTTGAGGAG 
101        G  T  E  F  H  Q  P  T  L  L  D  D  T  V  I  G  K  L  E  E   
 
361       CTGTCGGCGCTGGCCCCGTTGCACAACCCGCCGGCGGTACTGGGCATCAAGGTGGCACGC 
121        L  S  A  L  A  P  L  H  N  P  P  A  V  L  G  I  K  V  A  R   
 
421       AGATTGCTGGCCAATGTCGCGCACGTCGCGGTGTTCGATACGGCCTTTTTCCATGACTTG 
141        R  L  L  A  N  V  A  H  V  A  V  F  D  T  A  F  F  H  D  L   
 
481       CCCCCGGCGGCCGCGACCTATGCCATCGACCGCGACGTCGCCGACAGATGGCATATCCGC 
161        P  P  A  A  A  T  Y  A  I  D  R  D  V  A  D  R  W  H  I  R   
 
541       CGCTACGGATTTCATGGCACTTCACACCAATACGTCAGCGAGCGGGCCGCCGCCTTCCTG 
181        R  Y  G  F  H  G  T  S  H  Q  Y  V  S  E  R  A  A  A  F  L   
 
601       GGCCGCCCGCTCGACGGTTTGAATCAGATTGTGCTGCATCTGGGTAACGGTGCCTCCGCC 
201        G  R  P  L  D  G  L  N  Q  I  V  L  H  L  G  N  G  A  S  A   
 
661       TCGGCGATTGCCCGCGGCCGGCCGGTGGAAACGTCGATGGGCCTGACACCGCTTGAGGGC 
221        S  A  I  A  R  G  R  P  V  E  T  S  M  G  L  T  P  L  E  G   
 
721       TTGGTGATGGGCACCCGCAGTGGCGACCTGGACCCGGGCGTCATCAGCTACTTGTGGCGC 
241        L  V  M  G  T  R  S  G  D  L  D  P  G  V  I  S  Y  L  W  R   
 
781       ACCGCGAGGATGGGTGTCGAGGACATCGAATCGATGCTCAACCATCGGTCCGGGATGTTG 
261        T  A  R  M  G  V  E  D  I  E  S  M  L  N  H  R  S  G  M  L   
 
841       GGGTTGGCGGGGGAGCGGGATTTTCGCCGTCTACGACTAGTGATCGAAACCGGGGACAGG 
281        G  L  A  G  E  R  D  F  R  R  L  R  L  V  I  E  T  G  D  R   
 
901       TCAGCACAATTGGCGTATGAGGTGTTCATCCACCGGTTGCGCAAGTACCTTGGTGCCTAT 
301        S  A  Q  L  A  Y  E  V  F  I  H  R  L  R  K  Y  L  G  A  Y   
 
961       CTGGCGGTGTTGGGCCACACCGATGTGGTGAGCTTTACCGCCGGGATCGGCGAAAACGAT 
321        L  A  V  L  G  H  T  D  V  V  S  F  T  A  G  I  G  E  N  D   
 
1021      GCGGCGGTGCGGCGGGACGCGTTGGCTGGCCTTCAGGGGCTAGGTATCGCACTCGACCAA 
341        A  A  V  R  R  D  A  L  A  G  L  Q  G  L  G  I  A  L  D  Q   
 
1081      GACCGCAACCTGGGCCCGGGGCACGGCGCCCGGCGGATTTCGTCAGACGATTCACCGATC 
361        D  R  N  L  G  P  G  H  G  A  R  R  I  S  S  D  D  S  P  I   
 
1141      GCCGTGCTGGTGGTTCCCACGAATGAAGAACTGGCCATCGCCCGCGATTGCCTGAGGGTG 
381        A  V  L  V  V  P  T  N  E  E  L  A  I  A  R  D  C  L  R  V   
 
1201      CTGGGCGGACGCCGAGCGTAA 
401        L  G  G  R  R  A  *                                          
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4) Glycerol kinase 
1         ATGGGCCATCATCATCATCATCATCATCATCATCACAGCAGCGGCCATATCGAAGGTCGT 
1          M  G  H  H  H  H  H  H  H  H  H  H  S  S  G  H  I  E  G  R  
 
61        CATATGTCCGACGCCATCCTAGGAGAGCAATTGGCCGAGTCCTCGGATTTCATAGCCGCC 
21         H  M  S  D  A  I  L  G  E  Q  L  A  E  S  S  D  F  I  A  A   
 
121       ATCGACCAGGGCACCACCAGCACCCGCTGCATGATCTTCGATCACCACGGTGCCGAGGTG 
41         I  D  Q  G  T  T  S  T  R  C  M  I  F  D  H  H  G  A  E  V   
 
181       GCCCGCCACCAGCTCGAGCACGAGCAGATCCTGCCCCGGGCCGGCTGGGTGGAGCACAAC 
61         A  R  H  Q  L  E  H  E  Q  I  L  P  R  A  G  W  V  E  H  N   
 
241       CCGGTCGAGATCTGGGAGCGCACCGCGTCGGTGTTGATCTCGGTGCTCAACGCCACCAAC 
81         P  V  E  I  W  E  R  T  A  S  V  L  I  S  V  L  N  A  T  N   
 
301       CTATCGCCGAAAGATATTGCCGCGTTGGGGATTACCAACCAACGTGAGACGACGCTGGTA 
101        L  S  P  K  D  I  A  A  L  G  I  T  N  Q  R  E  T  T  L  V   
 
361       TGGAATCGGCACACCGGACGGCCCTACTACAACGCGATTGTATGGCAGGATACCCGCACC 
121        W  N  R  H  T  G  R  P  Y  Y  N  A  I  V  W  Q  D  T  R  T   
 
421       GACCGCATCGCGTCGGCGCTGGATCGAGACGGTCGTGGAAACCTGATCCGCCGCAAGGCG 
141        D  R  I  A  S  A  L  D  R  D  G  R  G  N  L  I  R  R  K  A   
 
481       GGCCTGCCGCCGGCAACTTATTTCTCTGGCGGCAAGCTGCAGTGGATCCTGGAAAATGTC 
161        G  L  P  P  A  T  Y  F  S  G  G  K  L  Q  W  I  L  E  N  V   
 
541       GATGGAGTCCGCGCGGCCGCCGAGAACGGCGACGCATTGTTCGGCACACCGGACACCTGG 
181        D  G  V  R  A  A  A  E  N  G  D  A  L  F  G  T  P  D  T  W   
 
601       GTGTTGTGGAATCTGACCGGCGGGCCGCGGGGGGGTGTGCATGTCACCGATGTAACCAAC 
201        V  L  W  N  L  T  G  G  P  R  G  G  V  H  V  T  D  V  T  N   
 
661       GCCAGCCGGACCATGTTGATGGATCTAGAGACGCTGGACTGGGACGACGAGCTGTTGTCG 
221        A  S  R  T  M  L  M  D  L  E  T  L  D  W  D  D  E  L  L  S   
 
721       TTGTTTTCGATACCTCGGGCCATGCTGCCCGAGATCGCATCGTCGGCGCCGTCGGAGCCT 
241        L  F  S  I  P  R  A  M  L  P  E  I  A  S  S  A  P  S  E  P   
 
781       TACGGTGTCACGCTGGCGACCGGGCCTGTCGGCGGTGAGGTGCCGATCACCGGAGTTCTC 
261        Y  G  V  T  L  A  T  G  P  V  G  G  E  V  P  I  T  G  V  L   
 
841       GGTGATCAGCATGCGGCCATGGTCGGTCAAGTCTGTCTGGCCCCAGGGGAGGCGAAAAAC 
281        G  D  Q  H  A  A  M  V  G  Q  V  C  L  A  P  G  E  A  K  N   
 
901       ACCTATGGGACCGGCAATTTTCTGCTGCTGAACACCGGTGAAACGATCGTGCGATCGAAT 
301        T  Y  G  T  G  N  F  L  L  L  N  T  G  E  T  I  V  R  S  N   
 
961       AACGGCCTGCTAACCACGGTGTGCTACCAATTCGGGAACGCTAAACCCGTGTACGCGCTT 
321        N  G  L  L  T  T  V  C  Y  Q  F  G  N  A  K  P  V  Y  A  L   
 
1021      GAAGGTTCGATCGCGGTGACCGGCTCGGCGGTGCAGTGGCTACGCGATCAGCTGGGCATC 
341        E  G  S  I  A  V  T  G  S  A  V  Q  W  L  R  D  Q  L  G  I  
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1081      ATCAGCGGCGCCGCACAGAGTGAGGCGCTGGCCCGCCAGGTCCCCGACAACGGCGGCATG 
361        I  S  G  A  A  Q  S  E  A  L  A  R  Q  V  P  D  N  G  G  M   
 
1141      TATTTCGTGCCGGCGTTTTCCGGGCTGTTCGCGCCATACTGGCGGTCCGATGCGCGCGGC 
381        Y  F  V  P  A  F  S  G  L  F  A  P  Y  W  R  S  D  A  R  G   
 
1201      GCGATCGTCGGGTTGTCGCGGTTCAACACCAACGCGCACCTGGCGCGCGCAACGCTGGAG 
401        A  I  V  G  L  S  R  F  N  T  N  A  H  L  A  R  A  T  L  E   
 
1261      GCGATCTGCTACCAGAGCCGCGATGTGGTGGACGCCATGGAAGCAGACTCCGGTGTTCGC 
421        A  I  C  Y  Q  S  R  D  V  V  D  A  M  E  A  D  S  G  V  R   
 
1321      CTGCAGGTGTTGAAGGTGGATGGCGGGATCACCGGCAACGACCTGTGTATGCAGATCCAG 
441        L  Q  V  L  K  V  D  G  G  I  T  G  N  D  L  C  M  Q  I  Q   
 
1381      GCCGACGTGTTGGGTGTGGATGTGGTGCGGCCGGTGGTCGCCGAGACCACCGCACTAGGT 
461        A  D  V  L  G  V  D  V  V  R  P  V  V  A  E  T  T  A  L  G   
 
1441      GTGGCCTACGCGGCGGGCTTGGCGGTCGGGTTCTGGGCGGCTCCGTCCGATCTGCGGGCC 
481        V  A  Y  A  A  G  L  A  V  G  F  W  A  A  P  S  D  L  R  A   
 
1501      AACTGGCGAGAGGACAAGCGGTGGACACCGACGTGGGACGACGACGAGCGTGCCGCGGGT 
501        N  W  R  E  D  K  R  W  T  P  T  W  D  D  D  E  R  A  A  G   
 
1561      TATGCCGGCTGGCGCAAGGCGGTGCAGCGGACCCTGGATTGGGTTGACGTGTCCTAA 
521        Y  A  G  W  R  K  A  V  Q  R  T  L  D  W  V  D  V  S  *      
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5) Thiamine monophosphate kinase 
1         ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCAT 
1          M  G  S  S  H  H  H  H  H  H  S  S  G  L  V  P  R  G  S  H  
 
61        ATGACCACTAAAGATCACTCACTTGCAACGGAGTCCCCGACGCTGCAGCAGCTCGGCGAG 
21         M  T  T  K  D  H  S  L  A  T  E  S  P  T  L  Q  Q  L  G  E   
 
121       TTCGCCGTGATCGACCGGCTGGTGCGGGGGCGCCGACAACCCGCCACGGTACTGCTCGGG 
41         F  A  V  I  D  R  L  V  R  G  R  R  Q  P  A  T  V  L  L  G   
 
181       CCCGGCGACGATGCCGCGCTGGTGTCTGCCGGCGATGGTCGCACTGTGGTGTCGACGGAC 
61         P  G  D  D  A  A  L  V  S  A  G  D  G  R  T  V  V  S  T  D   
 
241       ATGCTGGTGCAAGATAGTCACTTCCGGCTGGACTGGTCGACACCGCAGGACGTCGGCCGC 
81         M  L  V  Q  D  S  H  F  R  L  D  W  S  T  P  Q  D  V  G  R   
 
301       AAGGCGATCGCCCAGAATGCCGCCGACATCGAGGCGATGGGGGCGCGGGCCACCGCGTTC 
101        K  A  I  A  Q  N  A  A  D  I  E  A  M  G  A  R  A  T  A  F   
 
361       GTGGTCGGCTTTGGAGCACCCGCTGAGACGCCGGCGGCGCAGGCGAGCGCGTTGGTCGAC 
121        V  V  G  F  G  A  P  A  E  T  P  A  A  Q  A  S  A  L  V  D   
 
421       GGAATGTGGGAGGAGGCGGGGCGCATTGGTGCCGGCATCGTCGGCGGCGATCTGGTCAGC 
141        G  M  W  E  E  A  G  R  I  G  A  G  I  V  G  G  D  L  V  S   
 
481       TGCCGGCAGTGGGTGGTGTCGGTCACCGCGATTGGTGACCTTGACGGTCGTGCCCCGGTG 
161        C  R  Q  W  V  V  S  V  T  A  I  G  D  L  D  G  R  A  P  V   
 
541       CTGCGCTCCGGGGCGAAGGCCGGCTCGGTGCTGGCCGTCGTCGGTGAGCTGGGCCGCTCG 
181        L  R  S  G  A  K  A  G  S  V  L  A  V  V  G  E  L  G  R  S   
 
601       GCTGCTGGCTATGCGCTGTGGTGCAACGGGATTGAAGACTTCGCCGAACTGCGCCGCCGC 
201        A  A  G  Y  A  L  W  C  N  G  I  E  D  F  A  E  L  R  R  R   
 
661       CATTTGGTGCCGCAGCCGCCCTACGGCCACGGCGCGGCGGCCGCGGCTGTCGGGGCTCAA 
221        H  L  V  P  Q  P  P  Y  G  H  G  A  A  A  A  A  V  G  A  Q   
 
721       GCGATGATCGATGTCTCCGACGGGCTGCTCGCCGATCTGCGGCACATCGCCGAGGCATCC 
241        A  M  I  D  V  S  D  G  L  L  A  D  L  R  H  I  A  E  A  S   
 
781       GGCGTGCGCATCGACCTGTCCGCCGCGGCGTTGGCCGCTGACCGCGACGCTTTGACTGCG 
261        G  V  R  I  D  L  S  A  A  A  L  A  A  D  R  D  A  L  T  A   
 
841       GCCGCAACCGCTCTGGGCACCGACCCCTGGCCGTGGGTGCTAAGCGGGGGTGAAGATCAT 
281        A  A  T  A  L  G  T  D  P  W  P  W  V  L  S  G  G  E  D  H   
 
901       GCCCTGGTCGCCTGTTTCGTCGGTCCGGTGCCGGCCGGGTGGCGCACCATTGGCCGGGTT 
301        A  L  V  A  C  F  V  G  P  V  P  A  G  W  R  T  I  G  R  V   
 
961       CTCGACGGGCCGGCTAGGGTGCTGGTCGACGGCGAGGAGTGGACTGGATACGCGGGCTGG 
321        L  D  G  P  A  R  V  L  V  D  G  E  E  W  T  G  Y  A  G  W   
 
1021      CAATCGTTTGGGGAGCCAGACAATCAAGGTTCGCTAGGGTAA 
341        Q  S  F  G  E  P  D  N  Q  G  S  L  G  *    
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6) Ribokinase 
1         ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCAT 
1          M  G  S  S  H  H  H  H  H  H  S  S  G  L  V  P  R  G  S  H  
 
61        ATGGCAAACGCCAGTGAGACTAACGTCGGCCCCATGGCGCCCCGGGTGTGCGTGGTAGGC 
21         M  A  N  A  S  E  T  N  V  G  P  M  A  P  R  V  C  V  V  G   
 
121       AGCGTGAACATGGACCTGACGTTCGTGGTGGACGCGCTTCCGCGCCCCGGCGAGACGGTG 
41         S  V  N  M  D  L  T  F  V  V  D  A  L  P  R  P  G  E  T  V   
 
181       CTTGCGGCGTCGTTGACCCGAACGCCAGGCGGGAAGGGCGCCAACCAGGCGGTGGCCGCA 
61         L  A  A  S  L  T  R  T  P  G  G  K  G  A  N  Q  A  V  A  A   
 
241       GCGCGCGCAGGCGCGCAGGTACAGTTCTCCGGTGCATTCGGCGACGATCCAGCCGCCGCC 
81         A  R  A  G  A  Q  V  Q  F  S  G  A  F  G  D  D  P  A  A  A   
 
301       CAGCTGCGGGCCCACCTGCGCGCCAACGCCGTTGGACTGGACAGGACCGTCACGGTGCCC 
101        Q  L  R  A  H  L  R  A  N  A  V  G  L  D  R  T  V  T  V  P   
 
361       GGACCGAGCGGGACGGCGATTATCGTGGTCGATGCCAGCGCCGAGAACACCGTGCTGGTG 
121        G  P  S  G  T  A  I  I  V  V  D  A  S  A  E  N  T  V  L  V   
 
421       GCGCCGGGTGCCAATGCACATCTGACTCCGGTACCCTCGGCCGTCGCCAACTGCGATGTA 
141        A  P  G  A  N  A  H  L  T  P  V  P  S  A  V  A  N  C  D  V   
 
481       CTGTTGACCCAGTTGGAGATTCCTGTTGCAACCGCGCTGGCAGCCGCGCGGGCAGCCCAG 
161        L  L  T  Q  L  E  I  P  V  A  T  A  L  A  A  A  R  A  A  Q   
 
541       TCGGCCGATGCGGTTGTCATGGTCAACGCCTCCCCAGCCGGCCAGGATCGAAGCTCCTTG 
181        S  A  D  A  V  V  M  V  N  A  S  P  A  G  Q  D  R  S  S  L   
 
601       CAGGACTTGGCCGCTATCGCCGACGTGGTGATCGCCAACGAGCATGAGGCAAACGACTGG 
201        Q  D  L  A  A  I  A  D  V  V  I  A  N  E  H  E  A  N  D  W   
 
661       CCGTCGCCACCAACACATTTCGTGATCACCCTGGGTGTGCGCGGTGCCCGGTACGTCGGC 
221        P  S  P  P  T  H  F  V  I  T  L  G  V  R  G  A  R  Y  V  G   
 
721       GCGGACGGGGTGTTCGAGGTACCCGCCCCAACGGTAACGCCAGTGGATACCGCCGGCGCC 
241        A  D  G  V  F  E  V  P  A  P  T  V  T  P  V  D  T  A  G  A   
 
781       GGCGACGTATTTGCCGGGGTCCTTGCTGCGAATTGGCCGCGCAACCCAGGTTCGCCGGCC 
261        G  D  V  F  A  G  V  L  A  A  N  W  P  R  N  P  G  S  P  A   
 
841       GAGCGACTGCGCGCATTGCGGCGGGCCTGCGCTGCGGGTGCGCTGGCAACTTTGGTGTCC 
281        E  R  L  R  A  L  R  R  A  C  A  A  G  A  L  A  T  L  V  S   
 
901       GGTGTCGGCGACTGCGCACCGGCCGCCGCCGCGATCGATGCGGCCCTGCGAGCCAACCGC 
301        G  V  G  D  C  A  P  A  A  A  A  I  D  A  A  L  R  A  N  R   
 
961       CACAACGGTTCATAA 
321        H  N  G  S  *                                                
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7a) Aspartokinase-alpha 
1         ATGGCGCTCGTCGTGCAGAAGTACGGCGGATCCTCGGTGGCCGACGCCGAACGGATTCGC 
1          M  A  L  V  V  Q  K  Y  G  G  S  S  V  A  D  A  E  R  I  R  
 
61        CGCGTCGCCGAACGCATCGTCGCCACCAAGAAGCAAGGCAATGACGTCGTCGTCGTCGTC 
21         R  V  A  E  R  I  V  A  T  K  K  Q  G  N  D  V  V  V  V  V   
 
121       TCTGCCATGGGGGATACCACCGACGACCTGCTGGATCTGGCTCAGCAGGTGTGCCCGGCG 
41         S  A  M  G  D  T  T  D  D  L  L  D  L  A  Q  Q  V  C  P  A   
 
181       CCGCCGCCTCGGGAGCTGGACATGCTGCTTACCGCCGGTGAACGCATCTCGAATGCGTTG 
61         P  P  P  R  E  L  D  M  L  L  T  A  G  E  R  I  S  N  A  L   
 
241       GTGGCCATGGCCATCGAGTCGCTCGGCGCGCATGCCCGGTCGTTCACCGGTTCGCAGGCC 
81         V  A  M  A  I  E  S  L  G  A  H  A  R  S  F  T  G  S  Q  A   
 
301       GGGGTGATCACCACCGGCACCCACGGCAACGCCAAGATCATCGACGTCACGCCGGGGCGG 
101        G  V  I  T  T  G  T  H  G  N  A  K  I  I  D  V  T  P  G  R   
 
361       CTGCAAACCGCCCTTGAGGAGGGGCGGGTCGTTTTGGTGGCCGGATTCCAAGGGGTCAGC 
121        L  Q  T  A  L  E  E  G  R  V  V  L  V  A  G  F  Q  G  V  S   
 
421       CAGGACACCAAGGATGTCACGACGTTGGGCCGCGGCGGCTCGGACACCACCGCCGTCGCC 
141        Q  D  T  K  D  V  T  T  L  G  R  G  G  S  D  T  T  A  V  A   
 
481       ATGGCCGCCGCGCTGGGTGCCGATGTCTGTGAGATCTACACCGACGTGGACGGCATCTTC 
161        M  A  A  A  L  G  A  D  V  C  E  I  Y  T  D  V  D  G  I  F   
 
541       AGCGCCGACCCGCGCATCGTGCGCAACGCCCGAAAGCTCGACACCGTGACCTTCGAGGAA 
181        S  A  D  P  R  I  V  R  N  A  R  K  L  D  T  V  T  F  E  E   
 
601       ATGCTCGAGATGGCGGCCTGCGGCGCCAAGGTGCTGATGCTGCGCTGCGTGGAATACGCT 
201        M  L  E  M  A  A  C  G  A  K  V  L  M  L  R  C  V  E  Y  A   
 
661       CGCCGCCATAATATTCCGGTGCACGTCCGGTCGTCGTACTCGGACAGACCGGGCACCGTC 
221        R  R  H  N  I  P  V  H  V  R  S  S  Y  S  D  R  P  G  T  V   
 
721       GTTGTCGGATCGATCAAGGACGTACCCATGGAAGACCCCATCCTGACCGGAGTCGCGCAC 
241        V  V  G  S  I  K  D  V  P  M  E  D  P  I  L  T  G  V  A  H   
 
781       GACCGCAGCGAGGCCAAGGTGACCATCGTCGGGCTGCCCGACATCCCCGGGTATGCGGCC 
261        D  R  S  E  A  K  V  T  I  V  G  L  P  D  I  P  G  Y  A  A   
 
841       AAGGTGTTTAGGGCGGTGGCCGACGCCGACGTCAACATCGACATGGTGCTGCAGAACGTC 
281        K  V  F  R  A  V  A  D  A  D  V  N  I  D  M  V  L  Q  N  V   
 
901       TCCAAGGTCGAGGACGGCAAGACCGACATCACCTTCACCTGCTCCCGCGACGTCGGGCCC 
301        S  K  V  E  D  G  K  T  D  I  T  F  T  C  S  R  D  V  G  P   
 
961       GCCGCCGTGGAAAAACTGGACTCGCTCAGAAACGAGATCGGCTTCTCACAGCTGCTGTAC 
321        A  A  V  E  K  L  D  S  L  R  N  E  I  G  F  S  Q  L  L  Y   
 
1021      GACGACCACATCGGCAAGGTATCGCTGATCGGTGCCGGCATGCGCAGCCACCCCGGGGTC 
341        D  D  H  I  G  K  V  S  L  I  G  A  G  M  R  S  H  P  G  V   
 
1081      ACCGCGACGTTCTGTGAGGCGCTGGCGGCGGTGGGGGTCAACATCGAGCTGATCTCCACC 
100 
 
361        T  A  T  F  C  E  A  L  A  A  V  G  V  N  I  E  L  I  S  T   
 
1141      TCGGAGATCAGGATCTCGGTGTTGTGCCGCGACACCGAACTGGACAAGGCCGTGGTCGCG 
381        S  E  I  R  I  S  V  L  C  R  D  T  E  L  D  K  A  V  V  A   
 
1201      CTGCATGAAGCGTTCGGGCTCGGCGGCGACGAGGAGGCCACGGTGTACGCGGGGACGGGA 
401        L  H  E  A  F  G  L  G  G  D  E  E  A  T  V  Y  A  G  T  G   
 
1261      CGGTAA 
421        R  *       
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7b) Aspartokinase-beta 
1         ATGGAAGACCCCATCCTGACCGGAGTCGCGCACGACCGCAGCGAGGCCAAGGTGACCATC 
1          M  E  D  P  I  L  T  G  V  A  H  D  R  S  E  A  K  V  T  I  
 
61        GTCGGGCTGCCCGACATCCCCGGGTATGCGGCCAAGGTGTTTAGGGCGGTGGCCGACGCC 
21         V  G  L  P  D  I  P  G  Y  A  A  K  V  F  R  A  V  A  D  A   
 
121       GACGTCAACATCGACATGGTGCTGCAGAACGTCTCCAAGGTCGAGGACGGCAAGACCGAC 
41         D  V  N  I  D  M  V  L  Q  N  V  S  K  V  E  D  G  K  T  D   
 
181       ATCACCTTCACCTGCTCCCGCGACGTCGGGCCCGCCGCCGTGGAAAAACTGGACTCGCTC 
61         I  T  F  T  C  S  R  D  V  G  P  A  A  V  E  K  L  D  S  L   
 
241       AGAAACGAGATCGGCTTCTCACAGCTGCTGTACGACGACCACATCGGCAAGGTATCGCTG 
81         R  N  E  I  G  F  S  Q  L  L  Y  D  D  H  I  G  K  V  S  L   
 
301       ATCGGTGCCGGCATGCGCAGCCACCCCGGGGTCACCGCGACGTTCTGTGAGGCGCTGGCG 
101        I  G  A  G  M  R  S  H  P  G  V  T  A  T  F  C  E  A  L  A   
 
361       GCGGTGGGGGTCAACATCGAGCTGATCTCCACCTCGGAGATCAGGATCTCGGTGTTGTGC 
121        A  V  G  V  N  I  E  L  I  S  T  S  E  I  R  I  S  V  L  C   
 
421       CGCGACACCGAACTGGACAAGGCCGTGGTCGCGCTGCATGAAGCGTTCGGGCTCGGCGGC 
141        R  D  T  E  L  D  K  A  V  V  A  L  H  E  A  F  G  L  G  G   
 
481       GACGAGGAGGCCACGGTGTACGCGGGGACGGGACGGGTCGAGCACCACCACCACCACCAC 
161        D  E  E  A  T  V  Y  A  G  T  G  R  V  E  H  H  H  H  H  H   
 
541       TGA 
181        *   
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8) Shikimate kinase 
1         ATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCAT 
1          M  G  S  S  H  H  H  H  H  H  S  S  G  L  V  P  R  G  S  H  
 
61        ATGGCACCCAAAGCGGTTCTCGTCGGCCTGCCGGGCTCCGGCAAGTCCACCATCGGGCGC 
21         M  A  P  K  A  V  L  V  G  L  P  G  S  G  K  S  T  I  G  R   
 
121       CGGCTGGCCAAGGCGCTCGGGGTCGGCCTGCTCGACACCGACGTCGCGATCGAGCAGCGG 
41         R  L  A  K  A  L  G  V  G  L  L  D  T  D  V  A  I  E  Q  R   
 
181       ACCGGACGCAGCATCGCCGACATCTTCGCCACCGACGGGGAGCAGGAGTTCCGACGTATC 
61         T  G  R  S  I  A  D  I  F  A  T  D  G  E  Q  E  F  R  R  I   
 
241       GAGGAGGACGTGGTGCGCGCGGCACTGGCCGACCACGACGGTGTGCTGTCGCTCGGCGGC 
81         E  E  D  V  V  R  A  A  L  A  D  H  D  G  V  L  S  L  G  G   
 
301       GGCGCGGTGACCAGCCCCGGTGTGCGCGCGGCGCTGGCCGGCCACACCGTCGTCTACCTG 
101        G  A  V  T  S  P  G  V  R  A  A  L  A  G  H  T  V  V  Y  L   
 
361       GAGATCAGCGCCGCCGAGGGCGTGCGCCGCACCGGCGGCAACACCGTGCGCCCACTGCTG 
121        E  I  S  A  A  E  G  V  R  R  T  G  G  N  T  V  R  P  L  L   
 
421       GCCGGCCCCGACCGCGCCGAAAAATACCGCGCGCTGATGGCCAAGCGGGCACCGCTGTAC 
141        A  G  P  D  R  A  E  K  Y  R  A  L  M  A  K  R  A  P  L  Y   
 
481       CGGCGCGTCGCGACCATGCGAGTGGACACCAATCGCCGCAACCCCGGGGCGGTGGTCCGC 
161        R  R  V  A  T  M  R  V  D  T  N  R  R  N  P  G  A  V  V  R   
 
541       CATATCCTGTCGCGGCTGCAGGTTCCCAGCCCCAGCGAGGCGGCCACATGA 
181        H  I  L  S  R  L  Q  V  P  S  P  S  E  A  A  T  *            
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Appendix B 
 
 
Map of pGEM®-T Easy vector (Promega. 2010) 
 
 
Map of pET-16b vector (EMD Millipore. 2013) 
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Map of pET-20b vector (EMD Millipore. 2013) 
 
 
Map of pET-26b vector (EMD Millipore. 2013) 
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Map of pET-28a vector (EMD Millipore. 2013) 
 
 
Map of CDFDuet-1 vector (EMD Millipore. 2013) 
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Appendix C: Profinia Buffers 
 
BUFFER 1 (Wash Buffer 1, 2x), 250 ml  
600 mM  KCl   11.18 g  
100 mM  KH2PO4  3.04 g   
10 mM  Imidazole  0.17 g   
pH 8.0   
 
BUFFER 2  (Wash Buffer 2, 2x), 250 ml   
600 mM  KCl 11.18 g  
100 mM  KH2PO4 3.04 g  
20 mM  Imidazole 0.34 g  
pH 8.0 
 
BUFFER 3 (Elution Buffer, 2x), 250 ml    
600 mM  KCl 11.18 g  
100 mM  KH2PO4 3.04 g   
500 mM  Imidazole 8.51 g  
pH 8.0 
 
BUFFER 4 (Desalting Buffer, 5x), 250 ml 
685 mM  NaCl 10.01 g  
13.5 mM  KCl 0.252 g  
21.5 mM  Na2HP04 0.645 g  
40.5 mM  KH2P04 1.38 g  
pH 7.0 (pH 7.4 upon dilution) 
 
BUFFER 5 (Cleaning Solution 1, 2x), 250 ml 
1 M NaCl 14.61 g  
100 mM Tris 3.03 g 
pH 8.0 
 
BUFFER 6 (Cleaning Solution 2, 4x), 250 ml 
2 M NaCl 29.22 g  
400 mM NaOAc 8.20 g  
pH 4.5 
 
BUFFER 7 (Storage Buffer, 2x) 
20% EtOH 
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